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5ABSTRACT
Hyperthyroidism is defined as excess secretion of thyroid hormones by a diseased 
thyroid gland. The most common diseases causing hyperthyroidism are Graves´ 
disease, multinodular goiter and toxic adenoma. There are three different treatment 
modalities of hyperthyroidism –antithyroid drugs (ATD), radioactive iodine 
(RAI) and thyroidectomy. All these treatments have been used for several decades. 
Hyperthyroidism causes several disadvantageous changes in the metabolism, due 
to excess amount of circulating thyroid hormones. Based on the previous studies, 
hyperthyroid patients have an increased risk of cardiovascular diseases, even after 
achieving euthyroidism. Furthermore, there are studies suggesting an increased risk 
of cancer in patients treated for hyperthyroidism with RAI. It is unclear, whether 
the excess risk is due to hyperthyroidism, its treatment, or the shared risk factors of 
these diseases. 
The aim of this study was to assess cardiovascular and cancer morbidity and 
mortality in hyperthyroidism before and after the treatment, and to compare the long-
term outcome of patients treated with RAI and those treated with thyroid surgery.
This comparative cohort study included all the patients treated for 
hyperthyroidism in Finland during 1986-2007 with subtotal or total thyroidectomy 
(n=4334) and all the patients treated with RAI in Tampere University Hospital 
during the same period of time (n=1819). Three age- and gender-matched controls 
were obtained for each patient from the National Population Registry. Cancer 
diagnoses of the patients and the controls were obtained from the Cancer Registry, 
and hospitalizations for cardiovascular diseases from the hospitalization database of 
National Institute for Health and Welfare (HILMO).
Firstly, hospitalizations due to CVDs and the incidence of cancer until the 
treatment of hyperthyroidism were analyzed. Secondly, the hazard ratios (HR) for 
any new hospitalization and mortality due to CVDs and for the incidence of cancer 
after the treatment were estimated among all the hyperthyroid patients compared 
to the age- and gender-matched controls, and also in the RAI-treated patients 
compared to the thyroidectomy-treated patients. The results were adjusted for 
prevalent CVDs and prevalent cancers at the time of treatment. 
The main results of this study were that hyperthyroidism increased the risk of 
CVD-related hospitalizations, and the risk was sustained up to two decades after 
6treatment with RAI or surgery. Subtotal or total thyroidectomy was more effective 
in decreasing cardiovascular morbidity and mortality in hyperthyroid patients than 
treatment with RAI, and the patients treated with RAI had over twice as high CVD 
mortality rates compared to patients treated with thyroidectomy. Hypothyroidism after 
treatment with RAI, however, predicted better cardiovascular outcome. The overall 
risk of cancer in hyperthyroid patients was unchanged compared to age- and gender-
matched reference subjects, but there was an increased risk of gastric and respiratory 
tract cancers. The effect of treatment modality on cancer incidence was neutral.
As a conclusion, the increased risk of CVDs and cancer in hyperthyroid 
patients is associated to hyperthyroidism and shared risk factors, not the treatment 
modality. This underlines the importance of efficient treatment of hyperthyroidism 
in the future. Furthermore, disregarding the treatment modality, the patients 
treated for hyperthyroidism should be regarded as high-risk patients for CVDs and 
to some cancers and long-term follow-up should be arranged.
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8TIIVISTELMÄ
Hypertyreoosilla tarkoitetaan sairastuneen kilpirauhasen liiallista 
kilpirauhashormonien tuotantoa. Tavallisimpia syitä ovat Basedowin tauti, 
monikyhmystruuma ja yksittäinen toksinen adenooma. Hypertyreoosia voidaan 
hoitaa kolmella tavalla: tyreostaattisilla lääkkeillä, radioaktiivisella jodilla (RAI) tai 
kilpirauhasen osa- tai kokopoistolla. Kaikki nämä hoitomuodot ovat olleet käytössä 
jo vuosikymmeniä. Kilpirauhashormonit säätelevät elimistön aineenvaihduntaa, 
solujen kasvua ja energian tuotantoa. Aiempiin tutkimuksiin perustuen 
hypertyreoosiin sairastuneilla potilailla on lisääntynyt sydän- ja verenkiertoelimistön 
sairauksien riski vielä pitkään hoidon jälkeenkin. Osassa seurantatutkimuksia 
on tullut esiin myös lisääntynyt syöpäriski RAI-hoidetuilla potilailla. Toistaiseksi 
on ollut epäselvää, johtuuko lisääntynyt sairastuvuus hypertyreoosin ja 
sydänsairauksien tai hypertyreoosin ja syövän yhteisistä riskitekijöistä, vai itse 
sairastetusta hypertyreoosista tai sen hoitomuodoista. 
Tutkimuksen tarkoituksena oli selvittää hypertyreoosipotilaiden sairastuvuutta 
ja kuolleisuutta sydän- ja verenkiertoelimistön sairauksiin ja syöpään ennen ja 
jälkeen hypertyreoosin hoidon ja verrata näiden sairauksien riskiä kahden erilaisen 
hoitomuodon, RAI-hoidon ja kilpirauhasleikkauksen jälkeen.
Tähän vertailevaan kohorttitutkimukseen otettiin mukaan kaikki Suomessa 
vuosina 1986-2007 hypertyreoosin vuoksi kilpirauhasleikatut potilaat (n=4 
334) ja kaikki samaan aikaan Tampereen yliopistollisen sairaalan alueella 
hypertyreoosin vuoksi RAI-hoidetut potilaat (n=1 819). Jokaiselle haettiin 
kolme ikä- ja sukupuolivakioitua verrokkia Väestörekisterikeskuksesta. 
Tiedot potilaiden ja verrokkien syöpäsairastuvuudesta ja kuolleisuudesta 
haettiin Syöpärekisteristä ja tiedot sydän- ja verenkiertoelimistön sairauksista 
johtuvista sairaalahoitojaksoista Terveyden ja Hyvinvoinnin laitoksen (THL) 
Hoito- ja poistoilmoitusrekisterin (HILMO) tietokannasta. Ensin analysoitiin 
potilaiden sydän- ja verisuonisairauksiin liittyvät sairaalahoitojaksot ja syövän 
ilmaantuvuus hypertyreoosin hoitoon saakka. Sen jälkeen analysoitiin sydän-ja 
verisuonisairauksista johtuvan uuden sairaalahoitojakson ja uuden syövän 
riski ja sekä kuolleisuus verrattuna ikä- ja sukupuolivakioituihin verrokkeihin. 
Lisäksi verrattiin hypertyreoosin vuoksi RAI-hoidon saaneiden sairastuvuutta ja 
kuolleisuutta hypertyreoosin vuoksi leikattuihin potilaisiin. Tulokset vakioitiin 
9aiemmalla syöpäsairastuvuudella syövän suhteen ja aiemmalla sydän- ja 
verisuonisairauksien sairastuvuudella sydänsairauksien suhteen.
Saatujen tulosten perusteella hypertyreoosi lisäsi riskiä joutua sairaalahoitoon 
sydän- ja verenkiertoelimistön sairauksien vuoksi ja riski oli koholla vielä kahden 
vuosikymmenen ajan RAI-hoidon tai kilpirauhasleikkauksen jälkeen ikä- ja 
sukupuolivakioituihin verrokkeihin verrattuna. Kilpirauhasleikkaus vähensi 
tehokkaammin sydänsairastuvuutta ja kuolleisuutta hypertyreoosipotilailla 
kuin RAI-hoito ja RAI-hoidetuilla potilailla oli yli kaksinkertainen kuolleisuus 
leikattuihin potilaisiin verrattuna. Hypotyreoosi RAI-hoidon jälkeen merkitsi 
parempaa ennustetta.
Syövän ilmaantuvuudessa ja syöpäkuolleisuudessa ei ollut eroa potilaiden 
ja verrokkien välillä, mutta hengitystiesyöpien ja mahasyövän riski oli potilailla 
korkeampi kuin verrokeilla. Hoitomuodolla ei ollut vaikutusta syövän 
ilmaantuvuuteen tai syöpäkuolleisuuteen. 
Tämän tutkimuksen tuloksista voidaan päätellä, että hypertyreoosin 
sairastaneiden potilaiden lisääntynyt sydän- ja verisuonisairauksien ja maha- 
ja hengitystiesyöpien riski ei näyttäisi liittyvän hypertyreoosin hoitoon, vaan 
sairastettuun hypertyreoosiin sekä hypertyreoosin ja sydän- ja verisuonisairauksien 
ja hypertyreoosin ja tiettyjen syöpien yhteisiin riskitekijöihin. Saadut tulokset 
korostavat hypertyreoosin tehokkaan hoidon merkitystä tulevaisuudessa. Valitusta 
hypertyreoosin hoitomuodosta huolimatta, potilaita tulisi pitää sydän- ja 
verisuonisairauksien ja syövän suhteen korkean riskin potilaina hoidon jälkeenkin ja 
huolehtia pitkäaikaisseurannan toteutumisesta näiden sairauksien suhteen.
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ABBREVIATIONS 
131I  radioactive isotope 131 of iodine
AF  atrial fibrillation
CAD  coronary artery disease
CI  confidence interval
CO  cardiac output
CT  computed tomography
CVD  cardiovascular disease
Gy  Gray; unit for the absorbed dose of radiation
ICD  International Classification of Diseases
HILMO Hoito – ja poistoilmoitusrekisteri 
HR  hazard ratio
MBq  megabecquerel; unit for radioactivity (106 disintegrations per second)
mCi   millicurie; unit for radioactivity (13.7 x 107 disintegrations per second)
OR  odds ratio
RAI  radioactive iodine
RLN  recurrent laryngeal nerve
RR  rate ratio
SIR  standardized incidence ratio
SQRTPA Scandinavian Quality Register for Thyroid, Parathyroid and Adrenal   
  Surgery
STUK  Säteilyturvakeskus / Radiation and Nuclear Safety Authority
SV  stroke volume
THL  Terveyden ja hyvinvoinnin laitos /  
  National Institute for Health and Welfare
TSHRAb thyroid stimulating hormone receptor antibodies
TSH  thyrotropin
T3  triiodothyronine
T4  thyroxine
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INTRODUCTION
Hyperthyroidism, which refers to increased secretion of thyroid hormones by 
a diseased thyroid gland, is a common disease, with a prevalence of 2.5% in 
women and 0.6% in men (Bjoro et al., 2000). The most common causes for 
hyperthyroidism are Graves´ disease, multinodular goiter and toxic adenoma. 
Graves´ disease is responsible for 60-80% of cases (Weetman, 2000). The risk 
factors for Graves´ disease are smoking, stress, pregnancy and female sex (Kahaly 
et al., 2018). The proportion of toxic adenoma and toxic multinodular goiter as 
an etiology of hyperthyroidism increases with age and they are more common in 
iodine-deficient areas (Ross et al., 2016).
Thyroid hormones have direct and indirect effects on all parts of the 
cardiovascular system and affect growth and metabolism. Thyrotoxicosis 
causes several changes in the cardiovascular system and predisposes acutely to 
hypertension, heart failure and arrhythmias (Klein, Irwin & Danzi, 2016). 
The changes in cardiovascular system have been regarded as reversible, without 
persistent consequences after the treatment of hyperthyroidism. However, several 
long-term follow-up studies have reported increased cardiovascular morbidity 
and mortality even after the treatment (Franklyn et al.; 1991; Franklyn et al., 
2005; Flynn et al., 2006; Metso, Auvinen et al., 2007; Metso et al., 2008). 
Hypothyroidism after the treatment has been associated with better prognosis 
(Boelaert et al., 2013). There are also a few reports on increased incidence of 
different cancers and cancer mortality in hyperthyroid patients (Goldman et al., 
1988). However, conflicting results with decreased or unchanged total cancer 
incidence have also been reported (Franklyn et al., 1999).
There are three different options for the treatment of hyperthyroidism- 
antithyroid drugs (ATDs), thyroidectomy and RAI. All of these options have been 
used since 1940s and have their own advantages and disadvantages (Ross et al., 
2016). The previous long-term follow-up studies on CVD and cancer morbidity 
and mortality in hyperthyroidism after the treatment have included mainly 
patients treated with RAI. Therefore, it is unclear whether the increased morbidity 
and mortality are an outcome associated with the treatment with RAI or caused 
by hyperthyroidism per se. For example, in a study published by Metso et al, there 
was an association between the cancer risk and the dose of RAI administered 
17
(Metso, Auvinen et al., 2007), suggesting a long-term oncogenic effect of RAI. 
Previously, no long-term comparative studies on the outcome of the patients after 
different treatment modalities have been published. The aim of this thesis was to 
study the long-term outcome of the hyperthyroid patients and to compare the 
impact of two different treatment modalities, RAI and thyroidectomy, on the 
long-term outcome of the patients. 
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REVIEW OF THE LITERATURE
2.1 Hyperthyroidism
2.1.1 Definitions and epidemiology of hyperthyroidism and thyrotoxicosis
Hyperthyroidism is a significant disease affecting 2.5% of women and 0.6% of 
men (Bjoro et al., 2000). In the United States, the prevalence of hyperthyroidism 
is 1.2% (Singer et al., 1995) and in Finland about 1% (Sane, 2010). 
Hyperthyroidism refers to increased synthesis and secretion of thyroid hormones by 
the thyroid gland. Overt hyperthyroidism is defined as a subnormal or undetectable 
level of thyrotropin stimulating hormone (TSH) and increased level of T4 and/or 
T3. Overt hyperthyroidism may be preceded by subclinical hyperthyroidism, in 
which the level of TSH is decreased while the levels T4 and T3 are still within the 
normal range. Thyrotoxicosis is defined as an increased concentration of circulating 
thyroid hormones, i.e thyroxine (T4) and/or triiodothyronine (T3) and can also be 
caused by other reasons than hyperthyroidism (Ross et al., 2016).
2.1.2 Causes of hyperthyroidism and thyrotoxicosis
Thyrotoxicosis is usually caused by diseases affecting the thyroid gland, but may 
also be caused by other, non-thyroidal diseases or conditions. Graves´ disease, 
toxic multinodular goiter, toxic adenoma and destructive thyroiditis are the most 
common diseases causing hyperthyroidism. 
Graves´ disease is responsible for 80% of cases in Europe in iodine-rich areas, 
but in iodine-deficient areas 50% of hyperthyroidism is caused by nodular goiter 
(Ross et al., 2016). It is an autoimmune disease in which thyroid stimulating 
autoantibodies (TSHRab) bind to thyroid-stimulating hormone receptors causing 
thyroid hyperplasia and excess production and secretion of thyroid hormones 
by the thyroid gland (Kahaly et al., 2018). The etiology of Graves’ disease is not 
totally clear, but it is known to be multifactorial. Several associated genes have been 
recognized (De Leo et al., 2016). According to a Danish twin study, 79% Graves´ 
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disease is due to genetic factors and the rest is caused by environmental factors (Brix 
et al., 2001). The prevalence and concordance rate of hyperthyroidism in twin pairs 
has been studied in a cohort from Denmark (Brix et al., 2001) and a cohort from 
California, USA (Ringold et al., 2002). In the Danish study, 35% concordance was 
reported between monozygotic twins while in the Californian cohort, concordance 
rate for hyperthyroidism between monozygotic twins was 17% (Ringold et al., 
2002). Other risk factors for Graves´ disease include stress, smoking, pregnancy 
and female sex, and factors influencing the immune system have been suspected, 
for example infections and some drugs (Kahaly et al., 2018). Furthermore, thyroid 
damage or a deficiency of vitamin D or selenium may predispose to Graves´ disease 
(Marinò et al., 2015).
Toxic multinodular goiter and toxic adenoma are more common in iodine-
deficient areas and in older people (Carlé et al., 2011; Ross et al., 2016). In 
nodular thyrotoxicosis, thyroid nodule or nodules become autonomous and 
begin to produce excess of thyroid hormones despite the feedback from TSH or 
TSH-receptor antibodies (Ross et al., 2016). The progression of thyroid nodules 
may be accelerated by an excessive iodine intake for example due to amiodarone 
therapy. Almost 40% of the amiodarone molecule consists of iodine which may 
promote hyperthyroidism either by enhancing excessive production and secretion 
of thyroid hormones in a thyroid gland with a latent disease, or by causing 
a destructive thyroiditis with an accelerated release of previously produced, 
stored thyroid hormones (Capel et al., 2017). Other drugs that may induce 
hyperthyroidism include lithium and interferone _. 
The conditions that can result in thyrotoxicosis without hyperthyroidism 
are thyrotropin-producing pituitary tumours, struma ovarii, metastatic follicular 
thyroid cancer, thyrotoxicosis caused by HCG secreted during pregnancy or by a 
chorioncarcinoma (De Leo et al., 2016). 
Iatrogenic thyrotoxicosis may be caused by excessive or unnecessary use of 
levothyroxine (LT4) or liothyronine (LT3), either as a treatment of subclinical or 
clinical hypothyroidism or of other conditions misdiagnosed as hypothyroidism 
(i.e. fatigue, depression, weight gain). Normal thyroid gland produces mainly T4 
which converts to the active form T3 intracellularly by deiodinases. The standard 
therapy for hypothyroidism is LT4, and a vast majority of the patients respond 
to LT4 with relief of hypothyroid symptoms, and normalized levels of TSH, T4 
and T3. However, some patients continue having symptoms of hypothyroidism 
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despite normalized laboratory values. A few studies have been published comparing 
the effects of LT4 and LT3 with conflicting results (Grozinsky-Glasberg et al., 
2006; Joffe et al., 2007), but the current guidelines recommend LT4 as the first 
line therapy for hypothyroidism, due to its efficacy and favourable safety profile 
(Jonklaas et al., 2014; Kraut & Farahani, 2015).
2.1.3 Clinical presentations of hyperthyroidism
Thyroid hormones regulate energy and heat production and synthesis of several 
proteins affecting the metabolism of almost every organ in human body. They 
are essential to hepatic, cardiac, neurological and muscular functions. Classical 
symptoms caused by excess load of thyroid hormones are anxiety, fatigue, decreased 
weight, increased sweating, heat intolerance, palpitations, osteoporosis, mental 
disorders and tachycardia (Davies Terry F., Laurberg Peter, Bahn Rebecca S, 
2016). The severity of symptoms depends on the level of thyrotoxicosis, but the 
symptoms may be misleading or lacking, especially in the elderly (Boelaert et al., 
2010). Orbitopathy is associated with Graves´ disease and involves ca. 25% of 
the patients. The main symptoms of orbitopathy are exophthalmos (proptosis), 
periorbital edema and diplopia (Bartalena & Fatourechi, 2014).
2.2 Treatment of hyperthyroidism
2.2.1 Antithyroid drug therapy
2.2.1.1 Indication and contraindications
Antithyroid drugs (ATDs) are thionamide derivative drugs that inhibit the synthesis 
of thyroid hormones. ATDs (carbimatzole, methimatzole and propylthiouracil) are 
used as a medical therapy for hyperthyroidism, usually as a short-term treatment 
before RAI-therapy or surgery. As a primary treatment of hyperthyroidism, ATDs 
are used in children, young adults, seniors and in persons, who do not wish any 
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other treatment (Ross et al., 2016). They can also be used as a long-term treatment 
in pregnant or breast-feeding women and with significant eye symptoms in Graves´ 
disease (Cooper, 2005). ATDs, especially methimatzole and carbimatzole, are not 
recommended during the first trimester of pregnancy, due to the teratogenic effects 
occurring in 2-4% of pregnancies with ATDs (Alexander et al., 2017).
2.2.1.2 Side-effects of ATDs 
ATDs may cause cutaneous reactions, gastrointestinal symptoms and arthralgia 
as mild side effects in 5-25% of the patients. More serious side effects are rare, 
agranulocytosis occurring in 0.2-0.5% and hepatitis in 0.1-0.2% of the patients 
(Cooper, 2005). Although the ATDs are known to be safe in continued use up to 
10 years (Azizi et al., 2005), even the long-term ATD therapy is usually used only 
for 12-18 months.
2.2.1.3 Efficacy of the treatment
Since ATDs are not ablative therapies for hyperthyroidism, they have a high 
relapse rate compared to RAI or thyroidectomy. In a recent comparative study of 
720 patients with Graves´ disease, patients treated with ATDs had a relapse rate 
of 48% while those treated with RAI had a relapse rate of 8% and those with 
thyroidectomy 0% (Sundaresh et al., 2017). Similar relapse rate for ATDs (53%) 
was reported previously in a meta-analysis with 1402 patients with Graves´ disease 
(Sundaresh et al., 2013).
2.2.2 Radioactive iodine (RAI)
The administration of RAI has been used since the 1940s as a treatment modality 
for hyperthyroidism. Treatment with RAI (131 I) is based on the iodine uptake 
of thyroid gland and the aim of the treatment is to achieve euthyroidism or 
hypothyroidism by destroying a part of the functional tissue of the thyroid gland. 
RAI is given in liquid or as a capsule form of 131 I-labeled sodium iodide. RAI is 
actively transported into the thyroid follicular cells in which its beta emissions result 
in tissue necrosis. Tissue ablation is caused during the next 6-18 weeks or longer 
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and meanwhile hyperthyroidism may even worsen (Ross, 2011). The dose may be 
fixed or calculated individually based on the size of a thyroid gland (Ross, 2011).
2.2.2.1 Indications and contraindications
Treatment with RAI is used in all three major causes of hyperthyroidism as a 
permanent cure of the disease. It can also be used in relapses after ATDs or subtotal 
surgery. RAI is one of the first line treatment choices for most of the patients with 
hyperthyroidism (Ross et al., 2016). The main contraindications are pregnancy 
and lactation. As primary safety regulations, the patient has to avoid the company 
of children for five days and of pregnant women for 10 days, and minimize the 
contact time with other adults for five days after the administration of RAI (STUK, 
2013). The regulations and instructions vary between countries, but inability to 
follow the radiation safety precautions is a contraindication for the treatment (Ross, 
2011).
2.2.2.2 Efficacy and short-term side-effects of treatment with RAI
After the administration of RAI, euthyroidism develops for 50-95% of patients 
during 2-6 months (Franklyn et al., 1991). The most common side-effect is 
hypothyroidism, which develops for 6-15% of patients during the first year and 
for 70-78% of patients after a longer period of time (Franklyn et al., 1991; Metso 
et al., 2004). However, hypothyroidism may also be considered as a favourable 
outcome since it is easier to manage than a relapse of hyperthyroidism. RAI is 
cleared by the kidneys and renal failure may thus lead to a longer exposition of the 
body organs to radiation (Holst et al., 2005).
Other possible side-effects are thyroiditis, a painful condition harming 
about 1% of the patients and an evolving Graves´ disease after the treatment of 
multinodular goiter (Ross, 2011). Furthermore, the incidence of orbitopathy has 
been reported to increase after the treatment with RAI (Tallstedt et al., 1992). 
2.2.2.3 RAI and the risk of cancer 
As a long-term consequence of RAI-therapy, there is a suspicion of increased cancer 
incidence after the treatment. During the past 40 years, several studies with large 
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cohorts on cancer incidence and mortality after treatment of hyperthyroidism have 
been published. The first study included patients treated either with thyroidectomy 
or RAI (Hoffman et al., 1982), but other studies have mainly included patients 
treated with RAI for hyperthyroidism. Hoffman et al found no difference in the 
incidence of breast cancer, leukemia or all cancers between the two treatment 
groups, but a higher incidence of cancers in organs that concentrate RAI, ie. 
salivary glands, digestive tract, kidneys and bladder, was reported. Another 
American study with 1 762 hyperthyroid women treated mostly with RAI reported 
a small increase in the incidence of breast cancer in patients treated with RAI and 
an increase in pancreatic cancer (Goldman et al., 1988). A Swedish study with 
10 552 patients reported no increase in cancer incidence overall, but an increased 
incidence of lung (SIR 1.32), kidney (SIR 1.39) and stomach cancers (SIR 1.33) 
and a decreased incidence of malignant lymphoma (SIR 0.53) (Holm et al., 1991). 
Conflicting results, however, with a decreased or unchanged total cancer 
incidence were reported from Birmingham, England by Franklyn et al in 1999. 
The study of 7 417 patients treated with RAI found decreased cancer incidence and 
mortality in patients. A decreased risk of pancreas, bronchus, trachea and bladder 
cancers, and cancers of lymphatic and haemopoietic systems was reported, but 
there was an increased incidence of small bowel and thyroid cancers and increased 
mortality for these cancers (Franklyn et al., 1999).
 Metso et al. published several articles during 2004-2008 on morbidity and 
mortality after treatment of hyperthyroidism with RAI. In these studies, there 
were 2 793 patients treated with RAI for hyperthyroidism during 1965-2002 in 
Tampere University Hospital, Finland. One of the main results was an increased 
cancer incidence and mortality during 20 years of follow-up after treatment 
of hyperthyroidism with RAI. The overall cancer incidence was 25% higher in 
the patients treated with RAI compared to age- and gender-matched controls. 
Furthermore, the incidences of kidney cancer (RR 2.32), stomach cancer (RR 
1.75) and breast cancer (RR 1.53) were increased. The cancer incidence was higher 
in patients with higher doses of RAI, and there was a latency period of five years 
before the increase in cancer incidence (Metso, Auvinen et al., 2007). A paper 
reporting increased risk of cancer mortality with the same study cohort was also 
published in 2007 (Metso, Jaatinen et al., 2007). 
The results of the previous studies led to a discussion in Finland on whether it 
is safe to treat patients with RAI for hyperthyroidism (Metso, 2009) (Sane, 2010). 
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Later on, Hieu et al from Australia published a meta-analysis including all the 
studies mentioned above. In this large meta-analysis, there was no increase in the 
overall cancer risk, but the risk at some sites, such as the kidneys and the thyroid 
gland was significantly increased, with a statistically insignificant tendency to 
stomach cancer (RR 1.11, 95% CI 0.92-1.33). The increased risk was explained as 
a side-effect of ablative doses of RAI (Hieu et al., 2012).
2.2.3 Surgery
2.2.3.1 Indications and contraindications
In Finland, approximately 200 procedures are performed each year due to 
hyperthyroidism (HILMO database). The main reason for thyroid surgery is 
malignancy or a suspicion of malignancy, but thyroidectomy is also used as a 
treatment option for hyperthyroidism or as a treatment of goiter for compressive 
symptoms. A large goiter may compress the respiratory tract, esophagus or 
the recurrent laryngeal nerve. The main reasons for the surgical treatment of 
hyperthyroidism are an inadequate response to treatment with antithyroid 
medication or RAI, contraindications for RAI (e.g., severe Graves´ orbitopathy  
or pregnancy), and patient preference (Cooper, 2003; Ross et al., 2016).
2.2.3.2 Complications
The four main complications of thyroid surgery are hemorrhage, recurrent laryngeal 
nerve palsy, hypocalcemia and infections. During the first procedures, bleeding 
was the most fatal complication of thyroid surgery with 40% mortality rate. 
Afterwards, the techniques were developed first by Jaques-Louis Reverdin and then 
by Theodor Kocher, who received a Nobel Prize of Medicine for the understanding 
of the physiology and the surgical treatment of the thyroid gland (Fortuny et al., 
2015). Nowadays, severe intraoperative hemorrhage is rare due to new techniques 
and devices (Boger & Perrier, 2004). Re-bleeding after thyroidectomy occurred 
in 2.1% of cases in a large follow-up study with 3 660 thyroid operations in 26 
Scandinavian hospitals. The risk was associated with older age and male gender. 
In the same study, infection was detected in 1.6% of cases and unilateral recurrent 
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laryngeal nerve (RLN) palsy in 3.9% with recovering in most of the cases after 
six months of follow-up. The risk of nerve palsy was associated again with older 
age, but also with intrathoracic goiter, thyrotoxicosis and routine laryngoscopy 
(Bergenfelz et al., 2008). In a report from 2009, the complication rate for nerve 
palsy was 6.7% immediately after operation. After 12 months of follow-up, 
however, most of the nerve palsies had been recovered. The authors concluded that 
the recovery of RLN palsy is possible in 90% of cases (Dionigi et al., 2010). 
The complication rate of uni- or bilateral RLN palsy may be decreased by new 
techniques, like neuromonitoring of the RLN during the operation (Fortuny et al., 
2015). According to a report by Bergenfeltz et al including 5 252 patients registered 
to Scandinavian Quality Register for Thyroid, Parathyroid and adrenal Surgery 
(SQRTPA), the intraoperative nerve monitoring (IONM) did not decrease the risk 
of early nerve palsy, but was associated with a decreased risk of permanent nerve 
palsy during the follow-up (Bergenfelz et al., 2016).
Hypocalcemia is a major complication of thyroid surgery and most often 
caused by injury to parathyroid glands during operation. The positions of the 
parathyroid glands vary and it is essential to keep them in their original positions 
during the operation, to preserve their terminal vascularization (Duclos et al., 
2012). In a large study with 3 574 operations and 28 different surgeons, the 
risk of hypoparathyroidism was 2.7% and its prevalence depended on surgeons 
experience and age: the surgeons aged 35-50 years had smaller complication rates 
than older or younger surgeons (Duclos et al., 2012). The main risk factors for 
hypoparathyroidism are recurrent operations, central neck dissection and goiter 
size, as well as thyroiditis and Graves´ disease due to their inflammatory nature 
(Erbil et al., 2007; Bergenfelz et al., 2008). 
The complication rate in thyroidectomy is associated with the number of 
procedures the surgeon performs yearly. In a recently published study of 16 954 
patients with thyroidectomy for either thyroid cancer (47%) or a benign thyroid 
disease (53%), the cut-off threshold for the lowest complication rate was achieved, 
if the surgeon performed over 25 procedures yearly. In the study, 51% of the 
surgeons performed only one thyroidectomy per year, and the overall complication 
rate was 6% (Adam et al., 2017).
27
2.2.3.3 Efficacy of the treatment
Thyroidectomy as a treatment of hyperthyroidism has many advantages. The most 
important advantage is an almost immediate effect; the half-life of T4 is 7-8 days. 
Nowadays, thyroidectomy is preferred to a subtotal thyroidectomy to avoid a 
relapse in the remnant (Palit et al., 2000) (Wilhelm & McHenry, 2010). The other 
advantages of thyroidectomy as a treatment of hyperthyroidism are the availability 
of a tissue sample for histologic examination, removing target tissue for the 
TSHRAbs, avoiding radiation and its possible long-term effects, and a neutral or 
positive effect on Graves’ orbitopathy (Boger & Perrier, 2004; Fortuny et al., 2015). 
The risk of recurring hyperthyroidism is negligible after thyroidectomy, and surgery 
does not prohibit immediate pregnancy and lactation, contrary to RAI therapy 
(Boger & Perrier, 2004). 
In a meta-analysis of 35 studies and 7 241 patients with Graves´ disease 
treated with subtotal or total thyroidectomy, all the patients treated with total 
thyroidectomy became hypothyroid. Of the patients treated with subtotal 
thyroidectomy, 60% achieved euthyroidism and 26% became hypothyroid. 
Persistent or recurrent hyperthyroidism occurred in 8% of the patients during a 
mean follow-up of 5.6 years (range 32 months to 32 years) (Palit et al., 2000). 
The conclusion of the meta-analysis was that total thyroidectomy is safe and 
recommended particularly for severe Graves´ disease and large goiters. The studies 
with patients with hyperthyroidism caused by toxic adenoma or multinodular 
goiter were excluded from the meta-analysis (Palit et al., 2000). 
2.2.4 Current treatment strategies for hyperthyroidism
The treatment modalities of hyperthyroidism have not evolved over a half century. 
They are targeted to inhibit, destroy or remove the thyroid gland. Research on 
the etiology and pathogenesis of the disease is essential for the development of 
a targeted treatment that would cure the disease, without toxicity and without 
sustained damage to the thyroid gland. None of the current treatment modalities – 
RAI, antithyroid medication, or thyroidectomy - meets the criteria. However, they 
are the treatment options currently available and widely used. Some of the patients 
are even treated with all three modalities before achieving remission (Ross et al., 
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2016). ATDs are used before RAI or surgery and are the main treatment option for 
children or for people with comorbidities and relatively short life expectancy for 
other reasons than hyperthyroidism. 
An important factor affecting the treatment modality chosen is the correct 
diagnosis of the etiology of hyperthyroidism. Without an accurate diagnosis the 
treatment modality chosen might be disadvantageous to a patient (Ross et al., 
2016). Nevertheless, even the right diagnosis and the best possible treatment 
modality do not protect from the side-effects, discomfort or restrictions during and 
after the treatment. Therefore, the patient has to be given sufficient information on 
the possible side-effects, costs, length of the recovery phase and other disadvantages 
as well as on the advantages of the possible treatment options available. After that 
the treatment modality or modalities are chosen in collaboration with the patient 
and the physician (Ross et al., 2016).
2.3 Morbidity during thyrotoxicosis
2.3.1 The functions of the thyroid hormones in the cardiovascular system
Thyroid gland and heart have a connection through migration during embryology 
and thyroid hormones have direct and indirect effects in all parts of the cardiovascular 
system (Klein, I., 2012). The human thyroid gland synthesizes and secretes thyroid 
hormones, of which 85% is T4 and 15% T3. T4 is converted mainly in the liver to 
T3, which is the active form of thyroid hormone (Salvatore et al., 2016). Cardiac 
myocytes cannot metabolize T4 to T3, and all the changes in the cardiovascular 
system are dependent on the level of T3 in blood (Everts et al., 1996). 
There are specific transport proteins for T3 in the cell membranes. In the 
myocytes, T3 enters the nucleus and binds to nuclear receptors, which then bind 
to specific elements of the target genes. There are several T3-responsive genes in the 
heart, which encode several structural and regulatory proteins. The most important 
gene transcription-mediated reaction regulated by T3 in the heart is the production of 
sarcoplasmic proteins, calcium-activated ATPase (Ca2+ -ATPase) and phospholamban. 
The flux of Ca2+ in and out sarcoplasmic reticulum determines systolic contractility 
and diastolic relaxation of the heart. The active transportation of Ca2+ by Ca2+ 
29
-ATPase is regulated by phospholamban, and the activity of phospholamban is 
modified by its phosphorylation. Thyroid hormone inhibits the genetic expression 
of phospholamban and increases its phosphorylation, modulating the systolic 
contractility and the force of diastolic relaxation (Grais & Sowers, 2014). Thyroid 
hormone has also other functions in cardiac myocytes. T3 regulates the performance 
characteristics of various sodium, potassium and calcium channels, which may have 
inotropic and chronotropic effects on the heart (Klein, I. & Ojamaa, 1998). 
2.3.2 The effect of thyrotoxicosis on the cardiovascular system
Cardiac output (CO) is a term describing the volume of blood pumped by the 
heart per unit of time. It is calculated with the equation CO=Heart Rate x Stroke 
Volume (SV). Thus, the factors that modulate CO are the factors affecting heart 
rate and SV. CO is controlled by the oxygen demands of the tissues in the body. 
The primary factors influencing heart rate are autonomic innervation and hormonal 
actions. SV is modulated by heart size and contractility, gender, duration of the 
contractions, preload and afterload (vascular resistance) (Guyton and Hall, 2016). 
For example, CO increases during exercise mainly due to increased heart rate. 
Furthermore, in systolic heart failure CO decreases due to decreased contractility. 
In hyperthyroidism, CO increases remarkably as a result of increased heart 
rate and contractility, together with decreased peripheral resistance and diastolic 
blood pressure, and with increased venous return and preload (Klein, 2012). The 
systolic contraction and the force of diastolic relaxation are enhanced mainly by 
direct effects of T3 on the regulation of intracellular Ca2+ transport. The decrease 
in peripheral resistance leading to decreased diastolic blood pressure and decreased 
afterload results from direct effects of T3 in smooth muscle cells. 
Decreased diastolic blood pressure activates the renin-angiotensin-aldosterone 
system, leading to salt and fluid retention. Meanwhile, thyroid hormone also 
increases the production of erythropoietin leading to an increased red cell 
mass (Klein, 2012) (Grais & Sowers, 2014). As a combined effect of the latter two, 
the blood volume is increased, leading to increased preload of the heart and thus 
to increased stroke volume (the Frank-Starling law). Left ventricular hypertrophy 
may develop in the hyperthyroid heart as a compensatory mechanism to increased 
preload, heart rate and cardiac output (Dörr et al., 2005). 
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2.3.3 Cardiovascular morbidity in hyperthyroidism
Most changes in the cardiovascular system during a hyperthyroid state are meaningful 
reactions to meet the demands of increased energy metabolism and heat production 
in the body. As a result, however, the cardiovascular system uses its capacity already 
at rest, leading to exercise intolerance (Klein & Ojamaa, 1998; Klein, I. & Ojamaa, 
2001). Atrial fibrillation (AF), tachycardia, elevated blood pressure, increased blood 
volume and increased oxygen demands of the heart predispose to heart failure and 
to worsening of the symptoms of a coexisting heart disease (Klein & Ojamaa, 1998; 
Klein & Ojamaa, 2001; Klein & Danzi, 2016). Left ventricular hypertrophy is a 
complication of long-term hypertension and was found to be an independent risk 
factor for cardiovascular morbidity and mortality in the Framingham Heart Study 
(Manyari, 1990; Kannel & Cobb, 1992). 
Because thyroid hormones do not decrease pulmonary flow resistance, 
pulmonary pressure may increase. The pulmonary pressure may rise due to 
hypertension and left ventricular hypertrophy leading to diastolic dysfunction, or due 
to systolic dysfunction caused by high-output heart failure. These mechanisms have 
been present in heart failure and in rise of pulmonary pressure associated with both 
subclinical and overt hyperthyroidism (Biondi, 2012). 
Hyperthyroidism, even subclinical, is a strong risk factor for AF. The excess of T3 
shortens the atrial refractory period by altering cell membrane functions (Komiya et 
al., 2002) and also seems to increase supraventricular ectopic activity in hyperthyroid 
patients without previous heart disease (Wustmann et al., 2008). Both these factors 
are triggers for AF, and AF feeds itself by altering the electrical (Wijffels et al., 1995) 
and mechanical functions of the atria (Sparks et al., 1999) and also changes the atrial 
structure by causing fibrosis in the myocardium (Burstein & Nattel, 2008; Nattel 
et al., 2000). This remodeling of the atria prolongs arrhythmias and predisposes to 
relapses. 
Patients with hyperthyroidism are thus susceptible to AF and an episode of 
AF predisposes to recurrent AF, which explains the persisted risk of AF among the 
patients with treated hyperthyroidism. A large Danish population-based study of 
586 460 subjects showed that the risk of AF is associated with thyroid function 
across the spectrum of subclinical and clinical thyroid diseases, the incidence of 
AF increasing with a decreasing TSH level (Selmer et al., 2012). Likewise, another 
Danish study found an association between newly diagnosed AF and the risk of 
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future hyperthyroidism. In this study, euthyroid patients with new-onset AF during 
1997-2009 were followed up to 13 years. Of the patients with new-onset AF, 3% 
developed hyperthyroidism during the follow-up time, while the prevalence of 
hyperthyroidism was 1% in the control group (Selmer et al., 2013).
In another recently published large Danish study, including 85 856 hyperthyroid 
patients and ten age- and gender-matched controls for each patient, reported a higher 
prevalence of many cardiovascular events after the diagnosis of hyperthyroidism. 
The risk of cardiovascular events peaked during the first three months after the 
diagnosis of hyperthyroidism. The risk of AF and arterial embolism was 6 to 7-fold, 
but also the risk of venous thromboembolism, ischemic or non-ischemic stroke, and 
percutaneous coronary intervention was increased up to 2-3 -fold. The risk of almost 
any subgroup of cardiovascular diseases persisted during the mean follow-up time 
of 9.2 years. The risk of percutaneous coronary intervention (PCI) was no longer 
statistically significant after the first year (Dekkers et al., 2017).
The significance of thyroid hormone excess in atherosclerosis and coronary 
artery disease (CAD) is uncertain. There are a few clinical studies evaluating 
the risk and prevalence of atherosclerotic changes in coronary arteries related to 
the spectrum of thyroid function. An association of low normal serum free T4 
concentration and increased coronary artery calcium scores detected by multi-
detector computed tomography was reported by Kim et al in 2012, in 1 849 
euthyroid subjects without significant risk factors for CAD (Kim et al., 2012). In 
the Kangbuk Samsung health study (Park et al., 2016), 2 173 healthy subjects were 
followed for four years. Thyroid hormones and TSH levels were measured and 
coronary artery calcium score (CACS) was defined by multi-detector computed 
tomography (CT) at the beginning and at the end of the follow-up. Low normal 
baseline T4 level was reported to associate with increase in CACS during 4 years, 
but there was no association between FT3 or TSH levels on CACS progression. 
Furthermore, another study on prevalence of coronary artery stenosis in CT 
angiography showed an increased risk of coronary artery calcification in overt 
and subclinical hyperthyroidism. The study included 51 women with overt 
hyperthyroidism, 74 women with subclinical hyperthyroidism, and 619 euthyroid 
women. All the patients were evaluated with computed tomography angiography. 
More high-grade stenoses (39.2%, 37.8%, 24.2%; P=0.007), higher CACS (456.5, 
199.5, 155.9; P < 0.0001), and higher plaque burden were detected among women 
with overt and subclinical hyperthyroidism, compared to women in euthyroidism. 
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The patients with overt hyperthyroidism had the highest scores, but also the 
patients with subclinical hyperthyroidism had higher scores than euthyroid women. 
In line with the CT findings, after a 168 months of mean follow-up hyperthyroid 
women had had significantly more revascularizations compared to euthyroid 
women (Beyer et al., 2017). The prevalence of other risk factors for atherosclerosis 
or the mechanisms of increased risk of atherosclerosis related to overt or subclinical 
hyperthyroidism were not discussed in this paper.
2.3.4 Thyrotoxicosis and cancer
Thyroid hormones are essential for normal growth and metabolism, but may also 
have a role in tumor progression (Moeller & Führer, 2013). Thyrotoxicosis and 
hyperthyroidism have been linked to increased risk of cancer in several recent studies. 
The Rotterdam study included 10 318 patients with free T4 and TSH measurements, 
and reported an association between higher free T4 levels and any solid cancer (HR 
1.42), lung cancer (HR 2.33) and breast cancer (HR 1.77) (Khan et al., 2016). In a 
Taiwanese study including 17 033 patients with a new diagnosis of hyperthyroidism 
and twice as many matched euthyroid controls, the patients with hyperthyroidism 
had a higher risk of any cancer (HR 1.21) and thyroid cancer (HR 6.80) after 
adjustment for confounding factors during four years of follow-up (Yeh et al., 2013). 
Hellevik et al studied the association between cancer incidence and low TSH in 
a large population-based study of 29 691 Norwegian patients (Hellevik et al., 2009). 
TSH was measured at the beginning of the study, and cancer incidence was followed 
during the follow-up of nine years. Low TSH levels (<0.05 mU/L) were associated with 
an increased cancer risk (HR 1.34), compared to the euthyroid reference group. Of 
specific cancer-sites, there was an increased risk of lung (HR 2.34), breast (HR 1.20), 
prostate (HR 1.97) and colon cancer (HR 1.23) in the hyperthyroid patients. The 
results of this Norwegian study were adjusted for age and gender, as well as for smoking. 
Subclinical or overt hyperthyroidism have also been found to associate to 
increased risk of prostate cancer (Mondul et al., 2012) (Chan et al., 2017), breast 
cancer (Tosovic et al., 2012) (Søgaard et al., 2016), breast cancer mortality (Journy 
et al., 2017) and mortality for ovarian cancer (Minlikeeva et al., 2017). 
The increased risk of cancer in hyperthyroidism might be due to an impact 
of hyperthyroidism per se, or due to shared risk factors for thyroid nodularity, 
hyperthyroidism and cancer. Smoking is a well-known risk factor for cancer and also 
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a risk factor for hyperthyroidism. A meta-analysis reported an increased prevalence 
of Graves’ disease (OR 3.3) among current smokers compared to non-smokers, but 
no association was detected between smoking and multinodular goiter (Vestergaard, 
2002). In a substudy of Nurse’s Health Study II, current smoking (HR 1.93) and 
previous smoking (HR 1.23) were associated with Graves´ disease, with a dose-
dependent increase in incidence (Holm et al., 2005). 
In addition to smoking, atrophic gastritis and iodine deficiency are shared 
risk factors for cancer and hyperthyroidism. Atrophic gastritis associates with both 
autoimmune thyroid disease and gastric cancer (Centanni et al., 1999). Furthermore, 
hyperthyroidism itself might be a risk factor for gastric cancer, due to inhibition 
of gastric acid production and hypergastrinemia during thyrotoxicosis (Dahlberg 
et al., 1981; Centanni et al., 1999) , which is involved with carcinogenesis in the 
gastric mucosa (Watson et al., 2006). Venturi et al have published a short review on 
studies on iodine intake and gastric cancer and shown a correlation between iodine 
deficiency, goiter, and atrophic gastritis (Venturi et al., 2000). Gastric carcinoma is 
more prevalent in areas of iodine deficiency and also high in countries with excess 
iodine intake, such as Japan, China, and Korea (Song et al., 2018). Furthermore, 
iodine deficiency has been suggested to associate with the development of breast 
cancer (Venturi, 2001), and an excess iodine intake might inhibit or delay the 
development of breast cancer (Smyth, 2003). 
2.4 Morbidity and mortality after the treatment of hyperthyroidism
Both overt and subclinical hyperthyroidism are a significant burden to the human 
body and cause several acute and subacute changes affecting morbidity during 
hyperthyroidism. Most changes are regarded as reversible. However, several 
long-term follow-up studies have reported a persisting cardiovascular and cancer 
morbidity and/or increased all-cause, cardiovascular or cancer mortality after the 
treatment of hyperthyroidism. 
2.4.1 Mortality after the treatment of hyperthyroidism
There are a few studies offering data on all-cause mortality after treatment of 
hyperthyroidism (Hoffman et al., 1982; Goldman, 1990; Hall et al., 1993; Franklyn 
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et al., 2005; Flynn et al., 2006; Metso, Jaatinen et al., 2007; Bauer et al 2007) and a 
few on CVD or cancer mortality (Hall et al., 1993; Franklyn et al., 1998; Franklyn et 
al., 2005; Metso, Jaatinen et al., 2007). Most of the studies report increased all-cause, 
CVD or cancer mortality, but there are also results of unchanged risk of mortality 
in hyperthyroidism (Hoffman, McConahey, Diamond, & Kurland, 1982; Flynn et 
al., 2006). Most of the studies have included mainly patients treated with RAI. The 
oldest of the reports, a study by Hoffman et al (1982) included patients treated either 
with RAI or with thyroidectomy, and found no increased risk of mortality in patients 
treated with RAI (Hoffman, McConahey, Diamond, & Kurland., 1982). Increased 
CVD mortality has been reported after treatment with RAI (Goldman, 1990; Hall et 
al., 1993; Franklyn et al., 1998; Franklyn et al., 2005), but also after treatment with 
antithyroid drugs (Boelaert et al., 2013). 
2.4.2 Cardiovascular morbidity and mortality after the treatment of 
hyperthyroidism
There are a few large studies with rather similar results on CVD morbidity and 
mortality in patients with hyperthyroidism (Table 1). Nyirenda et al included 3 346 
patients with either Hashimoto´s thyroiditis, Graves´ disease or multinodular goiter 
in Edinburgh between 1981-2001. They reported an increased hospitalization 
rate for CVDs in all the diagnostic subgroups after treatment of hyperthyroidism 
compared to patients hospitalized for other reasons than hyperthyroidism (Nyirenda 
et al., 2005). The patients treated for Graves´ disease had 42% higher risk of 
hospitalization and the patients treated with multinodular goiter 50% higher risk. 
There was no increase in CVD mortality in this study. Flynn et al included 3 888 
hyperthyroid patients treated either with RAI, thyroidectomy or ATDs in Scotland 
during 1994-2001, and reported no increase in CVD mortality among hyperthyroid 
patients during 21 190 patient-years of follow-up. However, there was almost three-
fold (SIR 2.71) risk of arrhythmias in treated hyperthyroidism in this study (Flynn et 
al., 2006). The outcomes between different treatment groups were not compared. 
In a Finnish case-control cohort study including 2 611 hyperthyroid 
patients treated with RAI during 1969-2002, a 12% increase in the risk of CVD 
hospitalization was detected compared to age- and gender-matched control 
group (Metso et al., 2008). In the subgroup analyses of this study, the risk of 
hospitalization for AF (RR 1.35), cerebrovascular disease (RR 1.31), diseases of 
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other arteries and veins (RR 1.22), hypertension (RR 1.20) and heart failure (1.48) 
were also significantly increased, but the risk of CAD was unchanged. In a mortality 
study for the same cohort of patients, there was a 40% higher risk cerebrovascular 
mortality among hyperthyroid patients (Metso, Jaatinen et al., 2007). 
In most studies, patients have been treated mainly with RAI and only smaller 
studies have been published with other treatment modalities. In 2007 Osman et 
al reported the outcome of 393 patients treated with ATDs for hyperthyroidism, 
compared to a euthyroid age- and gender-matched control group. All the 
patients and controls were studied with 24-hour ECG monitoring, resting 
ECG, and measurement of blood pressure and pulse rate at the time diagnosis 
of hyperthyroidism, and these studies were repeated during the follow-up. Serial 
measurements of TSH, T4 and T3 were performed. The hyperthyroid patients 
had a higher prevalence of cardiovascular symptoms and findings – namely a 
higher blood pressure and pulse rate, and a higher prevalence of arrhythmia – 
during hyperthyroidism, but also after achieving euthyroidism compared to the 
control group (Osman et al., 2007). Muthukumar et al published in 2016 a rare 
prospective study on reversal of cardiovascular dysfunction after surgical treatment 
of hyperthyroidism (Muthukumar et al., 2016). They included 41 hyperthyroid 
patients selected to total thyroidectomy. The patients were examined with 
echocardiography and natriuretic peptide (NT-proBNP) before treatment, after 
achieving euthyroidism with antithyroid drugs before the surgery and three 
months after total thyroidectomy. Before any treatment, 63% of the patients had 
either pulmonary hypertension, dilated cardiomyopathy, heart failure or elevated 
NT-proBNP. After achieving euthyroidism with antithyroid drugs, 73% of the 
patients had recovered and three months after surgery 92% of patients had a 
complete recovery of cardiovascular function. 
There are few studies including patients treated with thyroidectomy for 
hyperthyroidism. A recent Swedish paper from Giesecke et al included 12 239 
hyperthyroid patients treated either with RAI or thyroidectomy during 1976-2000 
in Stockholm area (Giesecke et al., 2017). Patients treated with thyroidectomy for 
a non-toxic thyroid disease were used as a control group (n= 3 685), as well as the 
general Stockholm population. Most of the hyperthyroid patients were women 
(85%), over a half were treated for Graves´ disease (n =6 248) and the rest for a toxic 
nodular goiter. Cardiovascular morbidity and mortality were compared between 
the controls and the study groups but not between different treatment modalities. 
Overall cardiovascular morbidity consisting mostly of heart failure and ischemic 
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stroke was 12% higher and CVD mortality was 27% higher among hyperthyroid 
patients compared to both control groups. The patients treated for a toxic nodular 
goiter had the highest cardiovascular risk. 
Two previous studies have compared mortality rates after different treatment 
modalities of hyperthyroidism. Boelaert et al compared studied patients treated with 
antithyroid medication or RAI (Boelaert et al., 2013). The all-cause mortality rates 
were increased during the periods of thionamide treatment for hyperthyroidism 
and after less intensive treatment with RAI (not resulting in hypothyroidism 
and treatment with thyroxine replacement therapy). The existence of AF was 
an independent risk factor for increased mortality rate. However, after intensive 
treatment with RAI (resulting in hypothyroidism and thyroxin replacement 
therapy), the all-cause mortality rates did not differ between the patients and the 
controls. Similar results of the advantages of more aggressive treatment (resulting 
in hypothyroidism) have been reported also in other studies (Franklyn et al., 2005)
(Metso et al., 2008). Giesecke et al published recently a comparative study on 
mortality rates after treatment of hyperthyroidism either with RAI or thyroidectomy. 
They included 10250 patients treated with RAI and 742 patients treated with 
thyroidectomy and reported significantly lower all-cause mortality rates on the 
patients treated with thyroidectomy compared to patients treated with RAI during a 
mean of 16-22 years of follow-up (Giesecke et al., 2018).
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AIMS OF THE STUDY
The aim of this study was to clarify the long-term prognosis of hyperthyroid 
patients treated with thyroidectomy for hyperthyroidism and to compare the results 
to hyperthyroid patients treated with RAI.
The specific questions were:
1. Does hyperthyroidism and/or its treatment affect CVD morbidity and mortality?
2. Is there a difference in CVD morbidity or mortality between the patients treated 
for hyperthyroidism with thyroidectomy and those treated with RAI?
3. Does hyperthyroidism and/or its treatment affect cancer morbidity and 
mortality?
4. Is there a difference in cancer morbidity or mortality between the patients treated 
for hyperthyroidism with thyroidectomy and those treated with RAI?
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SUBJECTS AND METHODS
4.1 1. Subjects (I, II, III)
4.1.1 The patients treated with thyroidectomy
The present study is based on two different groups of patients treated for 
hyperthyroidism. The first group of 4 334 patients (3 719 women and 615 men) 
includes all the patients treated surgically for hyperthyroidism between January 
1986 and December 2007 in Finland. The patients were identified from the 
Finnish Hospital Discharge Registry (HILMO) maintained by the National 
Institute for Health and Welfare (THL). The nationwide register covering all 
surgically treated patients was computerized in 1986. The search for surgically 
treated patients was based on both the diagnosis of hyperthyroidism (International 
Classification of Diseases, 8th, 9th and 10th revisions, codes 242 and E05) and the 
procedure codes for total or subtotal thyroidectomy (based on NCSP, Nordic 
Classification of Surgical Procedure codes) 2504, 2505 and 2506 BAA25, BAA40, 
BAA50 and BAA60 for total or subtotal thyroidectomy depending on the year of 
the procedure). The etiological diagnoses of hyperthyroidism were obtained from 
HILMO database. The follow-up data for thyroid status was not available for 
operated patients.
4.1.2 The patients treated with RAI
The second group of patients consist of 1 819 (1 485 women and 329 men) patients 
treated with RAI between January 1986 and December 2007 in Tampere, Finland. 
These patients were identified from the database of Tampere University Hospital. 
Patients treated with RAI have been systematically registered in Finland only in 
Tampere University Hospital with a catchment population of 500 000 (10% of 
the Finnish population). Information on the etiology of hyperthyroidism, previous 
surgical treatment, the dates and doses of RAI treatments and the follow-up of 
thyroid function were recorded in the computerized register kept in Tampere 
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University Hospital since 1965. Following the RAI treatment, the thyroid status of 
the patients was monitored by blood samples every 1-3 months during the first year 
and subsequently at a 1-3 years interval. 
4.1.3 The reference subjects
The reference population was formed by choosing randomly three age- (+/- 6 
months) and gender-matched control subjects (n=18 432) for each patient from the 
comprehensive national Population Register. The control subject had to be alive at 
the time the patient was treated and reside in the same county. There were no other 
inclusion or exclusion criteria. 
4.2 Methods (I, II, III)
4.2.1 The etiology of hyperthyroidism
The etiology of hyperthyroidism for the patients treated with thyroidectomy 
was available from the HILMO database. For the patients treated with RAI the 
etiology of hyperthyroidism was obtained from the database of Tampere University 
Hospital. The classification to different etiological subgroups of hyperthyroidism 
was made according to the ICD-codes. The ICD-8 codes 2400A, 2410A 2420a, 
ICD-9 codes 2420A, 2420X, 4240A and ICD-10 codes E05 and E05.0 were 
classified as Graves´ disease, ICD-8 codes 2421a, 2421A, ICD-9 codes 2422a, 
2422A, 2422X and ICD-10 codes E05.1 and E05.2 as Nodular goiter and the rest 
of the diagnoses or patients without a specific diagnosis were classified as “Other”. 
4.2.2 The thyroid status of the patients
The thyroid status after the treatment was available only for the patients treated 
with RAI. Patients were classified as hypothyroid if biochemical evidence (low 
total T4 or free T4 and an elevated TSH) was associated with symptoms of 
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hypothyroidism and treatment with levothyroxine was started. Hyperthyroidism 
and a relapse after the treatment was recorded if biochemical evidence (high total 
or free T4 and TSH below 0.4mU/l) was associated with symptoms, if antithyroid 
medication was still needed one year after RAI or if a repeated RAI therapy was 
necessary. The remission was recorded if the patient was euthyroid or hypothyroid 
during the follow-up.
4.2.3 Hospitalization rates for cardiovascular diseases (I, III)
The lifetime causes of hospitalization, as well as the dates of hospital admissions 
were obtained from HILMO database maintained by THL, with deterministic 
record linkage based on the unique personal identification number assigned to 
all the residents of Finland. The HILMO database includes the hospitalizations 
(hospital admission requiring at least one overnight stay) and causes of 
hospitalization of the Finnish residents since January 1969, and the procedure codes 
since 1986. Recording diagnoses to the HILMO database is obligatory in Finland.
Both the primary and secondary diagnoses recorded at discharge from the 
hospital were used in the analysis. The diagnoses have been coded according 
to the Finnish version of the 8th revision of the International Classification of 
Diseases (ICD-8) in 1986, ICD-9 up to 1995, and the Finnish version of ICD-10 
thereafter. The equivalent codes were identified between the different version of 
ICDs and the causes of hospitalization were classified into ten major cardiovascular 
groups, which were analyzed separately: any cardiovascular disease (any CVD); 
hypertension; CAD; diseases of the pulmonary circulation; arrhythmias; heart 
failure; cerebrovascular diseases; diseases of arteries and veins (including for example 
arteriosclerosis obliterans, aortic aneurysms and dissections and thrombosis of 
arteries and veins), and valvular diseases and cardiomyopathies. Of the arrhythmias, 
AF was studied separately. 
The rates of hospitalizations among the patients and the controls were 
illustrated with Kaplan-Meier curves beginning 10 years before the treatment 
of hyperthyroidism. In addition, the odds ratios (OR) of hospitalization due to 
different CVDs until the treatment were analyzed (prevalent CVDs).
Secondly, the effect of the treatment on the hospitalizations and mortality due 
to CVDs was estimated by analyzing the new hospitalizations and deaths due to 
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CVDs after the treatment of hyperthyroidism, with the follow-up starting on the 
date of RAI administration or the date of thyroidectomy for the patients, and on 
the same date for the matched controls. The follow-up ended on the date of the 
first hospitalization due to different CVDs, the date of death, emigration, or the 
common closing date (May 31st, 2009), whichever occurred first. The results were 
adjusted for the prevalent CVDs at entry.
4.2.4 The incidence of cancer (II)
The lifetime cancer cases occurring among the patients and the controls were 
identified from the Finnish Cancer Registry using computerized record linkage, 
with the unique personal identification number as the key. In the cancer registry, 
cancers are classified according to the latest International Classification of Diseases 
for Oncology, ICD-O-3. We excluded benign and in situ tumors, as well as those 
with uncertain or borderline malignancy, and included only malignant primary 
tumors. Cancer diagnoses were classified into 18 topographic groups: mouth 
and pharynx, salivary gland, esophagus, gastric, intestinal, thyroid gland, liver 
and pancreas, respiratory tract, bladder and urinary tract, kidney, skin, nervous 
system, hematopoietic, breast, gynecological, and prostate cancers, and cancers of 
unspecified site.
The follow-up of the patients for cancer incidence started three months after 
the treatment, i.e., thyroidectomy or the first dose of RAI, and on the same day 
for the corresponding controls. The latency period of three months after the 
treatment was chosen to exclude cancers incidentally found in the thyroid gland 
after thyroidectomy (= occult thyroid cancers). The follow-up ended on the day of 
the cancer diagnosis, death, emigration from Finland, or the common closing date 
(December 31st 2009), whichever occurred first. 
Prevalent cancers at baseline, i.e., those diagnosed before the beginning of 
the follow-up, were excluded. Site-specific cancer incidence was calculated with 
follow-up until the diagnosis of site-specific cancer, regardless of any other cancer 
diagnosed. Regarding breast and gynecological cancers, the person-years at risk were 
counted only for women, and regarding prostate cancer, for men only.
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4.2.5 Mortality (I, II, III)
The dates and causes of death among the patients and the controls were obtained 
from Statistics Finland, using a computerized record linkage. The dates and 
causes of death of all Finnish citizens certified by a physician have been included 
in this register since 1971. The causes of death have been coded according to 
the International Classification of Diseases (ICD, versions 8-10). A translation 
between the different versions was made and the underlying causes of death were 
classified into nine groups: infectious diseases, malignant tumors, endocrine diseases, 
cardiovascular diseases, dementia, respiratory diseases, trauma, other causes of death 
and unknown causes of death. The underlying cause of death was used for the for the 
analysis of cause-specific mortality rates. The mortality for AF was analyzed by using 
both the underlying cause of death and in addition, the contributory cause of death. 
The follow-up for all-cause mortality and cardiovascular mortality continued until 
31st May 2009 (I, III) and for cancer mortality until 31st of December 2009 (II).
4.2.6 Comparison between the patients treated either with RAI or 
thyroidectomy (II, III)
Secondly, the effect of the treatment on the hospitalizations and mortality due 
to CVDs was estimated by analyzing the new hospitalizations and deaths due to 
CVDs after the treatment of hyperthyroidism, with the follow-up starting on the 
date of RAI administration or the date of thyroidectomy for the patients, and on 
the same date for the matched controls. The follow-up ended on the date of the 
first hospitalization due to different CVDs, the date of death, emigration, or the 
common closing date (May 31st, 2009), whichever occurred first. The results were 
adjusted for the prevalent CVDs at entry.
The comparison of hospitalization rates and mortality between patients 
treated with thyroidectomy or RAI was made by Cox regression analyses. Clinical 
differences between these study groups -age, gender, prevalent CVDs and the 
etiology of hyperthyroidism- were used as covariates to adjust for the differences 
between the groups.
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4.2.7 Statistical analysis
Statistical software Stata for Windows version 13 (StataCorp, College Station, 
Texas, USA) was used to calculate the hospitalization rates for various diseases. 
Cox regression analyses were performed using IBM SPSS Statistics for Windows, 
Version 19.0 (IBM Corp. Released 2010. Armonk, NY: IBM Corp.). A two-sided 
p-value of less than 0.05 was considered statistically significant. The differences in 
clinical characteristics (age, gender, etiology of hyperthyroidism) between patients 
treated with either RAI or thyroidectomy were estimated with a Mann-Whitney U 
and with a r -tests when appropriate. 
4.2.7.1 Statistical analysis of cardiovascular diseases (I, III)
The Kaplan-Meier analysis was used to illustrate the hospitalization rates 
before and after the treatment and for mortality rates after the treatment. 
Conditional logistic regression model was fitted to assess the odds ratios (OR) 
of hospitalization due to different CVDs until the treatment (prevalent CVDs) 
and the Cox regression analyses for the hazard ratios (HR) and 95% confidence 
intervals (95% CI) for CVD hospitalization and mortality rates after the 
treatment. The comparison of hospitalization rates and mortality between patients 
treated with thyroidectomy or RAI was made by Cox regression analyses using 
age, gender, prevalent CVDs and the etiology of hyperthyroidism as covariates to 
adjust for the differences between the groups.
4.2.7.2 Statistical analysis of cancer (II)
Cancer rates were calculated from the number of cancers divided by the 
corresponding person-years for both study groups. The ratio of the cancer 
incidence and mortality rates in the patients and the age- and sex-matched 
control group was estimated by the Mantel-Haenszel method. Adjustment 
for confounding factors was performed with Cox regression multivariate 
analyses. Cox regression analyses were done both with and without prevalent 
cancer diagnosis as a covariate to exclude the possibility of the prevalent cancer 
diagnosis affecting the results.
46
In order to analyze the impact of the treatment modality of hyperthyroidism 
(RAI or thyroidectomy) on cancer incidence and mortality among the hyperthyroid 
patients, the etiology of hyperthyroidism (Graves´ disease, nodular disease or 
unspecified), age and gender of the patients were used as covariates in Cox regression 
multivariate analyses. In these analyses, no controls were included. Cox regression 
analyses were done both with and without prevalent cancer diagnosis as a covariate 
to exclude the possibility of the prevalent cancer diagnosis affecting the results.
4.2.8 Ethical considerations
The study was undertaken in accordance with the Declaration of Helsinki. No 
informed consent could be obtained from the study subjects, because of the large 
number of participants and because many of them died before the data collection 
for the study. The ethics committee of the Tampere University Hospital District 
reviewed the study protocol. The National Institute of Health and Welfare 
(THL) gave a permission to use the data from the Hospital Discharge Registry, 
The Statistics Finland for the dates and causes of death derived from the data of 
Statistics Finland and the Population Registration Centre for choosing the control 
population from the data of the Population Registration Centre.
47
48
RESULTS
5.1 The clinical characteristics of the patients 
5.1.1 The patients treated with thyroidectomy
A total of 4 334 patients were treated for hyperthyroidism with total or subtotal 
thyroidectomy between January 1986 and December 2007 in Finland. Eighty-six 
per cent (n=3 719) of the patients were women and 14% (n= 615) were men. The 
median age of the patients and the reference group at the time of surgery was 46 
years in the whole group, 48 (interquartile range 33-61) years in men and 46 (IQR 
34-59) years in women (Table 2). Four per cent of the patients (179 patients) were 
under 20 years of age at the time of the operation. Twelve per cent (n =497) of the 
patients and 11% (n=1 421) of the controls deceased during the follow-up time for 
CVD (common closing day 31st May 2009) and a total of 146 subjects emigrated 
from Finland. Until the end of the follow-up period (common closing day 31st 
Dec 2009), there were 523 deaths among the patients and 1 496 deaths among the 
controls. The mean follow-up was 11.7 years for the patients and the controls for 
cancer morbidity and mortality; 10.3 years for the patients (IQR 5.9-17.2 years) 
and 11.6 years for the controls (IQR 5.9-17.2 years). The mean follow-up period 
for CVD morbidity and mortality was 11.5 years (IQR 5.6-17.1) for the patients 
and 11.5 years (IQR 5.6-17.2) for the controls.
The most common cause of hyperthyroidism among the operated patients was 
Graves´ disease. Hyperthyroidism was caused by a toxic nodular goiter (including 
toxic adenoma and multinodular goiter) in 39% of the patients and the rest of 
the patients were classified as “Other”. The most common etiological diagnosis in 
patients under 40 years of age was Graves´ disease and in patients older than 40 
years toxic nodular goiter (p < 0.001). The distribution of the etiological diagnoses 
was similar between men and women (Table 2).
There was a total of 4 454 thyroidectomies performed during 1986-2007, of 
which 69% (n=3 063) were subtotal and 31% (n= 1 391) total. Three patients had 
three subtotal thyroidectomies and 114 patients were operated twice during the 
follow-up time. Forty-four of the patients with two operations had first a subtotal 
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and then a total thyroidectomy, and 70 patients had only subtotal operations. Thus 
68% of the patients (n=2 943) had only subtotal operations and 31% (n=1 347) 
only total operations. Subtotal operations were more common in all age groups 
and etiological groups (III), but the proportion of total operations from all the 
operations performed increased during the follow-up time (Fig 1).
Table 2. Clinical characteristics of the hyperthyroid patients treated with 
thyroidectomy or radioactive iodine (RAI).
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Fig. 1. The amount of thyroidectomies due to hyperthyroidism during 1986-2007 
in Finland and the proportions of total and subtotal operations.
5.1.2 The patients treated with RAI
A total of 1 814 patients were treated for hyperthyroidism with RAI between January 
1986 and December 2007 in Tampere University Hospital. Eighty-two per cent 
(n=1 480) of the patients were women and 18% (n= 329) were men. The median 
age of the patients and the reference group at the time of treatment was 59 years in 
the whole group, 54 (interquartile range 39-68) years in men and 60 (interquartile 
range 45-72) years in women (Table 2). Twenty-eight per cent (n=491) of the 
patients and 24% (n=1 254) of the controls deceased during the follow-up time for 
CVD (common closing day 31st May 2009) and a total of 30 subjects emigrated 
from Finland until 31st of May 2009. Until the end of the follow-up period for 
cancer morbidity and mortality (common closing day 31st Dec 2009), there were 
512 death among the patients and 1 292 deaths among the controls. 
The mean follow-up period for cancer incidence and mortality were 10.3 years 
for the patients (IQR 5.5-14.5 years) and 10.6 years for the controls (IQR 5.7-14.9 
years). The mean follow-up period for CVD morbidity and mortality was 9.5 years for 
the patients (IQR 5.3-14.4 years) and 9.8 years for the controls (IQR 4.9-13.9 years). 
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Most of the patients treated with RAI had Graves´ disease, every fifth of the 
patients had nodular goiter (including toxic adenoma and multinodular goiter) and 
the rest of the patients (26%) were classified as “Other” (Table 2).
The total dose of RAI administered varied between 78MBq and 2264MBq, the 
mean dose was 323MBq and the median dose 259MBq. Most patients (n=1 442, 
79%) had only one treatment, 15% two treatments, 3.4% three treatments and the 
rest of the patients had four or more repetitive doses of RAI. In Tampere University 
Hospital, there were 38 patients treated first with RAI and then operated on (2% 
of the RAI-treated patients), and 145 patients treated surgically prior to treatment 
with RAI (8%). The information on overlapping of two treatment modalities was 
not available from other Finnish hospitals. 
5.2 Cardiovascular morbidity 
5.2.1 The risk of cardiovascular diseases before the treatment of 
hyperthyroidism (I, III)
5.2.1.1 The patients treated with thyroidectomy
The risk of hospital admission due to any CVD increased among both the patients 
and the controls during the whole follow-up. The difference between the two 
groups increased until the treatment of hyperthyroidism with thyroidectomy, 
becoming statistically significant five years before the thyroidectomy as illustrated 
by modified Kaplan-Meier analysis (Fig 2, Panel A). Until the thyroidectomy 
the patients had a 50% increase in the risk of hospitalization due to any CVD, 
compared to the controls (Table 3). The risk of hospitalization due to CVDs was 
increased in most of the subgroups of CVDs studied expect for ischemic heart 
disease (including acute myocardial infarctions), diseases of other arteries and veins, 
cerebrovascular diseases or diseases of pulmonary circulation compared to the 
control group. 
The most frequent subgroup of CVD associated with the increased 
hospitalization before the treatment of hyperthyroidism was hypertension. 
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The difference in hospitalizations with hypertension between the patients and 
the controls increased prior to the thyroidectomy (Fig 2, Panel B) and the 
hospitalization rate was twice as high in the patients as among the controls by 
the time of the operation (Table 3). The second most frequent indication for 
hospitalization was arrhythmias, of which AF was the most common diagnosis 
(81% of arrhythmias). The difference in the rates of hospitalizations due to AF 
increased towards the time of thyroidectomy (Fig 2, Panel C), the rate being 
almost five times higher in the patients at the time of thyroidectomy. The risk of 
hospitalization due to heart failure by the time of thyroidectomy was increased 
twofold and the risk of valvular diseases or cardiomyopathies was 57% higher 
among the patients compared to the reference group (Table 3).
Table 3. The odds ratios for cumulative hospitalization rates prior to the treatment 
due to different cardiovascular diseases in patients treated with RAI and in patients 
treated with thyroidectomy, compared with the age- and sex-matched controls.
	 76+*,<.:2*4.6-78.:2*6-5A7,*:-2*4-2;.*;.;26,4=-260>*4>=4*:-2;.*;.;*6-,*:-275A78*<1A
0-'('>*4=.;*:.;<*<2;<2,*44A;2062/2,*6<
RAI-treated patients (n=1 814) 
vs. 
controls (n=5 441) 
Thyroidectomy-treated patients (n=4 334) 
vs. 
controls (n=12 991) 
%2',06%3&5-%2',3(%3( !--;#*<27 8>*4=.
!--;#*<27
 8>*4=.
6A,*:-27>*;,=4*:-2;.*;. 1.81 (1.61-2.01) < 0.001 1.50 (1.37-1.64) < 0.001 
A8.:<.6;276 1.50 (1.23-1.84) < 0.001 2.05 (1.67-2.51) < 0.001
44*::1A<152*; 4.31 (3.52-5.27) < 0.001 3.93 (3.20-4.81) < 0.001 
<:2*4/2+:244*<276 5.86 (4.64-7.40) < 0.001 4.60 (3.72-5.67) < 0.001 
2;.*;.;7/*:<.:2.;*6->.26; 1.15 (0.99-1.33) 0.068 1.10 (0.95-1.28) 0.212 
7:76*:A*:<.:A-2;.*;. 1.67 (1.36-2.05) < 0.001 0.80 (0.56-1.15) 0.412 
.:.+:7>*;,=4*:-2;.*;.; 1.60 (1.23-2.07) < 0.001 1.12 (0.95-1.32) 0.231 
.*:</*24=:. 2.86 (2.19-3.72) < 0.001 1.92 (1.22-3.00) 0.050 
'*4>=4*:-2;.*;.;*6-,*:-275A78*<12.;
 3.52 (2.14-5.77) < 0.001 1.57 (0.98-2.51) 0.056 
2;.*;.;7/8=4576*:A*:<.:2.; 1.63 (0.85-3.14) 0.145 1.56 (0.80-3.04) 0.213 
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5.2.1.2 The patients treated with RAI
The risk of hospitalization due to CVDs increased among the patients and the 
controls during the follow-up time. The difference between the patients and the 
controls due to all cardiovascular indications started to increase years before the 
RAI treatment and by the time of the first treatment it was 1.81-fold in the patients 
compared to the controls (Fig. 2, Panel D and Table 3). 
The most frequent subgroup of CVD associated with hospitalization 
was hypertension. The difference between the patients treated with RAI and 
their controls increased prior to the treatment and the hospitalization rate was 
50% higher until it (Fig. 2, Panel E). The second most frequent indication for 
hospitalization was arrhythmias, of which AF was the most common. The difference 
in the risk of hospitalization due to AF increased years before the treatment with 
RAI (Fig. 2, Panel F) and by the time of it was almost six-fold (Table 3).
There was no difference in the hospitalization rates in diseases of arteries and 
veins or the diseases of pulmonary circulation between the patients and the controls 
prior to the treatment of hyperthyroidism. The risk of hospitalization due to CAD, 
cerebrovascular diseases, heart failure and valvular diseases and cardiomyopathy was 
substantially higher by the time of treatment among the patients (Table 3).
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Fig. 2. Cumulative hospitalization rate due to different cardiovascular diseases by 
time 10 years before and about 23 years after thyroidectomy (Panels A-C) or after 
RAI (Panels D-F) in patients treated for hyperthyroidism compared with the age 
and sex-matched control group (Log rank test).
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5.3 The risk of cardiovascular hospitalization after the treatment of 
hyperthyroidism 
5.3.1 The patients treated with thyroidectomy (I)
The risk of new hospitalization due to any CVD remained significantly higher 
among the patients after thyroidectomy, when adjusted for hospitalization preceding 
thyroidectomy (HR 1.15, 95% CI 1.06-1.24). The incidence of new hospitalization 
due to hypertension (HR 1.23, 95% CI 1.08-1.41), all arrhythmias (HR 1.25, 95% 
CI 1.07-1.47), heart failure (HR 1.17, 95% CI 1.01-1.50) and valvular diseases 
and cardiomyopathies (HR 1.55, 95% CI 1.17-2.04) was significantly higher in 
the patients, when adjusted for prevalent CVDs due to the given disease prior to 
the surgical treatment. There was no significant difference in hospitalization rates 
between the patients and the controls due to new-onset AF (HR 1.15, 95% CI 0.96-
1.39), CAD (1.03, 95% CI 0.87-1.19), cerebrovascular diseases (HR 1.19, 95% CI 
0.99-1.41), diseases of other arteries or veins (HR 1.09, 95% CI 0.96-1.25) nor due 
to diseases of pulmonary circulation (HR 0.78, 95% CI 0.53-1.15).
In subgroup analyses including only the patients treated either with subtotal or 
total thyroidectomies and their own age- and gender-matched controls, the patients 
treated with total thyroidectomy did not have statistical difference in the risk of any 
CVD hospitalization compared to their controls after treatment of hyperthyroidism 
(RR 1.16, 95% CI 0.98-1.37). Nevertheless, the patients treated with subtotal 
thyroidectomy had a higher risk of any CVD hospitalization (HR 1.09, 95% CI 
1.00-1.08, p=0.043) compared to their controls.
In a Cox regression analysis including only the patients with hyperthyroidism, 
male gender (HR 1.23, 95% CI 1.05-1.46), age at the time of surgery (HR 1.06, 
95% CI 1.06-1.07/year) and prevalent CVD (RR 2.19, 95% CI 1.91-2.50) 
predicted hospitalization due to any CVD after thyroidectomy, but the surgical 
technique (subtotal or total thyroidectomy) or the etiology of hyperthyroidism did 
not have a statistically significant impact on the risk of CVD hospitalization.
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5.3.2 The patients treated with RAI (III)
After the treatment of hyperthyroidism with RAI, the risk of new hospitalization 
due to any CVD remained significantly higher among the patients up to two 
decades, when adjusted for hospitalization preceding RAI (HR 1.23, 95% CI 
1.13-1.34). The incidence of new hospitalizations due to CAD or the diseases of 
pulmonary circulation was not significantly increased, but new hospitalization 
due to hypertension, arrhythmias, heart failure, cerebrovascular diseases, diseases 
of other arteries and veins and valvular diseases and cardiomyopathies were 
significantly higher in the patients compared to age- and gender-matched controls, 
when adjusted for prevalent CVD due the given disease (Table 4).
The patients treated with RAI were divided in two groups based on the 
outcome of treatment with RAI. A total of 856 patients became hypothyroid 
during the follow-up time and started a treatment with levothyroxine. The rest of 
the patients (n=935) became euthyroid or had a relapse of hyperthyroidism during 
the follow-up period. The risk of hospitalization due to any CVD was significantly 
increased in both of the groups. 
In the subgroup analyses of different CVDs, the risk of hypertension, 
cerebrovascular diseases, heart failure, valvular diseases or cardiomyopathies 
were not significantly increased in the patients treated more effectively with RAI 
(resulting in hypothyroidism), and the CAD was decreased (HR 0.70, 95% CI 
0.52-0.94), but the risk of diseases of other arteries and veins was increased. Among 
the patients treated less effectively with RAI (not resulting in hypothyroidism), the 
risk of CAD, hypertension, all arrhythmias, cerebrovascular diseases, heart failure 
and valvular diseases or cardiomyopathies were increased (Table 4).
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5.3.3 The effect of the treatment modality on CVD hospitalization (III)
The risk of CVD hospitalization after the treatment of hyperthyroidism was 
higher among the RAI-treated patients compared to the patients treated with 
thyroidectomy, adjusted for age, gender and prevalent CVDs (HR 1.14, 95% 
CI 1.03-1.26). Additional adjustment for the etiology of hyperthyroidism did 
not change the result (HR 1.17, 95% CI 1.05-1.30) (Table 5). The risk of 
hospitalization due to arrhythmias (HR 1.32, 95% CI 1.12-1.57) and new-onset 
AF (HR 1.40, 95% CI 1.16-1.68) was also increased in the RAI-treated patients 
compared to the surgically-treated ones, but there were no significant differences 
in the other subgroups of CVDs (Table 5). 
The patients treated more effectively with RAI (resulting in hypothyroidism) 
and the patients treated less effectively with RAI (not resulting in hypothyroidism) 
were compared with the patients treated with thyroidectomy in a Cox regression 
analysis, and adjusted with age, gender, prevalent CVDs and the etiology of 
hyperthyroidism. The patients treated effectively with RAI had no difference 
in the risk of any CVD hospitalizations compared to the patients treated with 
thyroidectomy (RR 0.95, 95% CI 0.82-1.09) (Table 5). In the analyses of 
subgroups of CVDs, the risk of CAD was even lower (HR 0.70, 95% CI 0.52-0.94) 
in the patients treated effectively with RAI compared to the patients treated with 
thyroidectomy, but the risk of diseases of the pulmonary circulation was higher. The 
number of the hospitalizations in the latter analysis was small. The patients treated 
ineffectively with RAI, however, had a higher risk of any CVD hospitalizations 
compared to the patients treated with thyroidectomy, similarly to the main analyses, 
but also an increased risk of hospitalization due to heart failure (Table 5).
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5.4 The risk of cancer after treatment of hyperthyroidism (II)
5.4.1 Cancer morbidity
There were 469 (7.3%) hyperthyroid patients and 883 (4.7%) persons among 
their controls, who had at least one cancer diagnosis before the beginning of the 
follow-up, i.e. before thyroidectomy or the first RAI treatment, or up to three 
months afterwards. Among the patients, 32% (n=151) of the prevalent cancers 
and among the control subjects 1% (n=26) were thyroid carcinomas (ICD-O-3 
code C73.9), most of them occult thyroid carcinomas found incidentally in the 
thyroidectomy for a benign disease without prevalent cancer suspicion. After 
excluding these diagnoses, 318 (5.2%) patients had prevalent cancer diagnosis, 187 
(4.3%) in the surgical group and 478 (3.7%) among their control subjects and 
131 patients (7.2%) in the RAI group and 379 (7.0%) among their controls at the 
beginning of the follow-up.
A total of 651 (10.2%) new cancers were diagnosed in the patients and 1 882 
(10.4%) among the controls during the average of 10 years of follow-up. There was 
no significant difference in cancer incidence between the patients and the controls 
(RR 1.05, 95% CI 0.96-1.15) (Table 6). The figures were similar in women (RR 
1.05, 95% CI 0.95-1.16) and in men (RR 1.04, 95% CI 0.85-1.28). In the analysis 
of specific cancer sites, the risk of respiratory tract cancers (RR 1.46, 95% CI 1.05-
2.02), and stomach cancer (RR 1.64, 95% CI 1.01-2.68) were increased among the 
patients with hyperthyroidism compared to the control group (Table 6). 
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5.4.2 The impact of the etiology of hyperthyroidism on cancer incidence (II)
All the patients treated for hyperthyroidism (ignoring the treatment modality) were 
analyzed together by the etiological subgroups. There was a tendency towards an 
increased cancer risk in the patients with a nodular thyroid disease, but it did not 
reach statistical significance (RR 1.13, 95% CI 0.99-1.28, p=0.0792). However, 
increased risk of breast cancer (RR 1.36, 95% CI 1.02-1.81, p=0.0387), respiratory 
tract cancer (RR 1.79, 95% CI 1.13-2.84, p=0.0114) and kidney cancer (2.62, 
95% CI 1.25-5.11, p=0.0083) were associated with a nodular disease, but not with 
Graves´ disease or with hyperthyroidism of unspecified etiology (Table 7).
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5.4.3 Patients treated with thyroidectomy and cancer
In separate analyses of cancer morbidity on patients treated with thyroidectomy 
compared to their respective controls, there was an increased risk of respiratory 
tract cancer, skin cancer and stomach cancer, but the overall risk of cancer was not 
increased. The risk of gynecological cancers was reduced (Table 8).
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5.4.4 Patients treated with RAI and cancer
Among the patients treated with RAI, there were 131 (7.2%) persons who already 
had at least one cancer diagnosis before the beginning of the follow-up ie. before the 
first treatment with RAI or up to three months afterwards. During the follow-up 
time there were 232 new cancers among the patients. The total dose of RAI 
administered for one patient varied between 8MBq and 2 264MBq, and the median 
dose was 259MBq. Most of the patients (n=1 442, 79%) had only one treatment. 
In an analysis including only the patients treated with RAI and their respective 
controls, there was no increased risk of cancer (RR 1.02, 95% CI 0.88-1.18, 
p=0.808) or any specific cancer sites (Table 9). The rate ratios for specific cancer sites, 
however, were similar to the risk ratios of patients treated with thyroidectomy but 
the number of cancers was smaller due to a smaller number of patients. There was 
no correlation between cancer incidence and the dose of RAI administered. In a Cox 
regression analysis performed only on the patients treated with RAI, the age at the 
time of first treatment with RAI (HR 1.05, 95% CI 1.04-1.06/year) and male gender 
(HR 1.74, 95% CI 1.27-2.38) predicted cancer diagnosis. However, the prevalent 
cancer diagnosis (HR 1.28, 95% CI 0.82-1.99) or the dose of RAI (HR 1.00, 95% 
CI 1.00-1.00) did not have a statistically significant effect on cancer incidence.
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5.4.5 The impact of treatment modality (RAI or thyroidectomy)  
on cancer incidence (II)
The evaluation of the impact of treated hyperthyroidism and its treatment 
modality on cancer incidence was done by Cox regression analyses. The first 
analysis included all the patients treated for hyperthyroidism either with RAI 
or thyroidectomy and all the controls. Age, gender, hyperthyroidism, and 
prevalent cancer were used as covariates. A previous cancer diagnosis (RR 1.29, 
95% CI 1.12-1.49), male gender (RR 1.55, 95% CI 1.41-1.72) and increasing 
age (RR 1.06/year, 95% CI 1.06-1.06) predicted the risk of cancer, but treated 
hyperthyroidism did not (RR 1.06, 95% CI 0.97-1.16). The second analysis 
assessed the effect of the treatment modality and the etiological subgroup of 
hyperthyroidism on cancer incidence. The age at the time of treatment (HR 1.06/
year, 95% CI 1.05-1.06) and male gender (HR 1.49, 95% CI 1.22-1.81) predicted 
the risk of cancer and there was also a tendency towards an increased risk in 
patients with a nodular thyroid disease (HR 1.19, 95% CI 0.99-1.43). The type 
of treatment (HR 0.86, 95% CI 0.86-1.20 for RAI compared to thyroidectomy), 
however, was not associated with the risk of cancer. 
5.5 Mortality in hyperthyroid patients
5.5.1 Overall and CVD mortality (III)
A total of 11.4% (n=497) of the patients and 10.9% (n=1 421) of the controls 
deceased during the follow-up. Overall mortality (RR 1.05, 95% CI 0.95-1.16) or 
mortality for CVDs (RR 0.91, 95% CI 0.77-1.07) was not increased among the 
patients compared to the controls. The mortality for CVDs was unaffected when 
adjusted for prevalent CVDs in a Cox regression analysis. The result was similar 
in Kaplan-Meier analysis (Fig. 3, Panel C, p=0.228). The mortality rates did not 
differ between the patients and the controls, when analyzed separately in men and 
women or in different subgroups of CVDs (data not shown). 
Overall mortality (HR 1.22, 95% CI 1.08-1.43, p=0.003) and CVD mortality 
(HR 1.24, 95% CI 1.08-1.43), were higher among the patients treated with RAI 
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for hyperthyroidism compared to the age- and gender -matched control group 
(Fig. 3 Panel B, p=0.004). However, adjustment for prevalent CVDs in Cox 
regression analysis attenuated the CVD mortality to insignificant (HR 1.07, 95% 
CI 0.92-1.23). 
In the subgroup analyses of mortality, the risk of overall mortality (HR 1.42, 
95% CI 1.27-1.60, p < 0.001) and CVD mortality (HR 1.23, 95% CI 1.05-1.44, 
p=0.011) (Fig 3, Panel E, p > 0.001) were increased in the patients treated ineffectively 
with RAI (not resulting in hypothyroidism) compared to age- and gender-matched 
control group. CVD mortality was adjusted to prevalent CVDs in the Cox regression 
analysis. On the contrary, the risk of both, overall mortality (HR 0.74, 95% CI 
0.57-0.96, p=0.026) and CVD mortality (RR 0.62, 95% CI 0.42-0.92, p < 0.001) 
were significantly lower in the patients treated with RAI leading to hypothyroidism 
compared to the age- and gender-matched control group in a Cox regression analysis 
with prevalent CVDs as a covariate. In a Kaplan-Meier analysis (without adjustment 
for prevalent CVDs) on patients treated effectively with RAI, the mortality for CVDs 
was comparable to the controls group (Figure 3, Panel D, p=0.053). 
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Fig. 3. Cumulative cardiovascular mortality rate by time since the treatment of 
hyperthyroidism in the different groups of patients compared with the age and  
sex-matched control group (Log rank test).
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5.5.2 The comparison between the patients treated with thyroidectomy and RAI
In a Cox regression analysis, cardiovascular mortality was significantly higher in the 
patients treated with RAI compared to the patients treated with thyroidectomy, when 
adjusted for age, gender and prevalent CVDs (HR 2.05, 95% CI 1.69-2.48). The 
result was unaffected when analyzed separately in different subgroups of etiologies; 
Graves´ disease (HR 1.86, 95% CI 1.22-2.84, p=0.004), nodular disease (HR 2.83, 
95% CI 2.11-3.80, p < 0.001) and other etiologies (HR 2.96, 95% CI 1.95-4.51, p 
< 0.001), or by including only the patients treated with subtotal (HR 2.05, 95% CI 
1.67-2.52) or total thyroidectomy (HR 3.17, 95% CI 2.16-4.65). 
CVD mortality was also analyzed in subgroups of CVD although the number 
of deaths in the subgroups was small leading to wide confidence intervals. The 
patients treated with RAI had a higher risk of CVD mortality for CAD (HR 2.47, 
95% CI 1.88-3.24, p < 0.001), AF (HR 3.68, 95% CI 1.11-12.18, p =0.033), 
cerebrovascular diseases (HR 2.55, 95% CI 1.69-3.84, p < 0.001) and valvular 
diseases and cardiomyopathies (HR 3.47, 95% CI 1.86-6.48, p < 0.001) compared 
to the patients treated with thyroidectomy, but not for hypertension (HR 1.23, 
95% CI 0.30-5.12, p=0.77) or heart failure (HR 1.99, 95% CI 0.60-6.60, p 
=0.259). All the results were adjusted for age, gender, prevalent CVDs and the 
etiology of hyperthyroidism. 
In an analysis including only the patients treated effectively with RAI (resulting in 
levothyroxine-treated hypothyroidism) and the patients treated surgically, the risk of 
death due to any CVD was significantly lower in the RAI-treated patients compared 
to those treated surgically, adjusted for age, gender and prevalent CVDs (RR 0.29, 
95% CI 0.20-0.43). The mortality for CVD was not analyzed in subgroups of CVDs 
due to the small number of deaths. However, when these patients were compared 
only to the patients treated with total thyroidectomy, there were no difference in the 
risk of CVD mortality (HR 0.58, 95% CI 0.34-1.00). In this analysis, there was 
no statistically significant difference either in the subgroup of patients with nodular 
disease compared to the patients with Graves´ disease (HR 1.48, 95% CI 0.75-2.92). 
Furthermore, in an analysis including only the patients with Graves´ disease treated 
effectively with RAI (resulting in levothyroxine-treated hypothyroidism) and the 
Graves´ disease patients treated surgically with total thyroidectomy, the risk of death 
due to any CVD was statistically insignificant in the RAI-treated patients, adjusted for 
age, gender and prevalent CVDs (1.37, 95% CI 0.51-3.70).
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5.5.3 Cancer mortality (II)
There was no difference in cancer mortality in an analysis including all the patients 
treated for hyperthyroidism (either with thyroidectomy or RAI) compared to the 
control group (RR 1.09, 95% CI 0.95-1.26). There was no difference in cancer 
mortality in male (RR 1.04, 95% CI 0.76-1.42) or female patients (RR 1.11, 95% 
CI 0.95-1.30), patients treated with thyroidectomy (RR 1.19, 95% CI 0.99-1.42, 
p=0.0565) or patients treated with RAI (RR 0.96, 95% CI 0.78-1.22, p =0.8824) 
compared to their respective controls. 
In a Cox regression analysis of cancer mortality including the patients and 
controls, treated hyperthyroidism was not significantly associated with death from 
cancer (RR 1.04, 95% CI 0.91-1.20), but older age at the time of treatment (RR 1.08, 
95% CI 1.07-1.08/year), male gender (RR 1.77, 95% CI 1.52-2.07) and a previous 
cancer diagnosis (RR 4.29, 95% CI 3.71-4.97) increased the risk of cancer death. 
In the analysis comparing the two treatment groups (excluding the controls), 
the age at the time of treatment (RR 1.08 /year, 95% CI 1.07-1.09) and a previous 
cancer diagnosis (RR 3.45, 95% CI 2.60-4.56) predicted cancer mortality, 
but the treatment modality RR 0.99, 95% CI 0.75-1.30 for RAI compared to 
thyroidectomy) or any of the etiological subgroups of hyperthyroidism did not.
5.6 Geographical differences between the study groups
Due to geographical differences between the two study groups, additional analyses 
were made to evaluate the possible effect of regional differences in the treatment of 
CVDs in Finland. Among the group treated with thyroidectomy, there were 241 
patients treated in Tampere University Hospital with 723 controls. When the Cox 
regression analyses on CVD hospitalizations among the thyroidectomized patients 
were performed including only these patients, the risk of any CVD hospitalization 
was comparable to the main result (HR 1.13, 95% CI 0.85-1.46, p=0.370).  
To test further whether the differences in CVD hospitalizations could be due 
to the geographical differences, some of the analyses were performed including 
only the control groups. There was no difference in the risk of hospital admission 
due to CVDs when the controls of the RAI-treated patients were compared to the 
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controls of the thyroidectomized patients, adjusted for age, gender and prevalent 
CVDs (HR 0.97, 95% CI 0.91-1.03), excluding any significant effect of the 
geographical difference on the results. Similarly, there was no difference in the risk 
of CVD mortality, when the controls of the RAI-treated patients were compared 
to the controls of the thyroidectomy-treated patients, adjusted for age, gender and 
prevalent CVDs (HR 0.98, 95% CI 0.89-1.12).
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DISCUSSION
6.1 Major findings of this study
6.1.1 Cardiovascular morbidity and mortality in hyperthyroidism
Considering the CVD morbidity and mortality, there are two main results in this 
study. The first main result is that the patients treated with thyroidectomy had 
an increased risk of CVD morbidity compared to their age- and gender-matched 
control group. The second main result is that the patients treated with RAI 
remained at a markedly increased risk after the treatment, compared to the patients 
treated with thyroidectomy. The first main result strengthens the hypothesis that 
the increased cardiovascular morbidity is not caused by the treatment, but by the 
disease, hyperthyroidism per se. The second main result may help in understanding 
the mechanisms behind the increased CVD risk.
In this study, the risk of CVDs already increased several years before the 
treatment of hyperthyroidism in both treatment groups. The risk was attenuated 
by both treatment modalities. The increased CVD morbidity, still sustained up 
to two decades after the treatment of hyperthyroidism in both treatment groups, 
highlighting the significant effect of hyperthyroidism per se. 
A hyperthyroid state causes stress to the cardiovascular system. Most changes 
in the cardiovascular system during hyperthyroidism are adaptive responses to 
increased energy metabolism and heat production in the body. Nevertheless, as a 
result of this adaptation, the cardiovascular system is strained already in the resting 
conditions, leading to exercise intolerance even in otherwise healthy persons 
(Klein & Ojamaa, 1998; Klein & Ojamaa, 1998). AF, tachycardia, elevated blood 
pressure, increased blood volume and increased oxygen demands of the heart 
predispose to heart failure and to worsening of the symptoms of a coexisting heart 
disease (Klein & Ojamaa, 2001; Klein, 2012; Klein & Danzi, 2016). 
Similar results of an increased CVD morbidity even before the diagnosis of 
hyperthyroidism have been reported in a recent Danish study, emphasizing the 
importance of a timely diagnosis of hyperthyroidism (Brandt et al., 2013b). This 
study included 2 631 hyperthyroid patients, 375 twin pairs with one hyperthyroid 
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and one euthyroid twin and a three-fold group of age- and gender-matched 
controls. An increased risk of CVDs (OR 1.65), lung diseases (OR 1.53) and 
diabetes (OR 1.43) was detected before the diagnosis of hyperthyroidism in this 
large study with a six years` follow-up time. The risk remained increased even after 
the diagnosis of hyperthyroidism, but this study did not report on the treatments 
the patients received for hyperthyroidism. The overall morbidity was also increased 
in hyperthyroid twins compared to euthyroid twins (OR 1.16). 
The genetic exposition for CVDs or other diseases could not be studied 
because of the insufficient power for the subgroup analyses of morbidity. The 
impact of genetics on mortality was studied in a larger twin pair study of 926 
hyperthyroid patients with a euthyroid or a hyperthyroid twin sibling (Brandt 
et al., 2012). In this study, there was an increased risk of overall mortality in 
hyperthyroid patients compared to their dizygotic twin siblings. The monozygotic 
twin pairs, however, had a similar risk of overall mortality despite the other sibling 
being hyperthyroid (Brandt et al., 2012). The authors suggest that genetic factors 
may have an impact on mortality in hyperthyroidism, as previously reported on 
obesity and mortality (Carlsson et al., 2011), although they state that this matter 
needs to be studied further.
6.1.2 The impact of treatment modality on cardiovascular morbidity and 
mortality
One of the most important findings in this study was an impact of treatment 
modality on CVD morbidity and mortality. The increased CVD morbidity and 
mortality in patients treated with RAI compared to patients treated with subtotal 
or total thyroidectomy in this study helps in understanding the mechanisms 
behind the association between hyperthyroidism and CVDs. In the present study, 
CVD morbidity was 14% higher and CVD mortality twice as high in RAI-treated 
patients compared to the patients treated with thyroidectomy, adjusted for the 
clinical features (age, gender, the etiology of hyperthyroidism and prevalent CVDs 
prior to the treatment). The excess risk was eliminated by an effective treatment 
with RAI, resulting in hypothyroidism. A similar result with a better prognosis after 
treatment with thyroidectomy compared to treatment with RAI has been published 
by Giesecke et al in 2018. They reported recently higher all-cause mortality rates 
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in patients treated with RAI compared to patients treated with thyroidectomy in 
a comparative study including 10250 patients treated with RAI and 742 patients 
treated with thyroidectomy (Giesecke et al., 2018).
There are several possible reasons for increased CVD morbidity and mortality 
in the RAI-treated patients compared to those treated with thyroidectomy. After the 
treatment with RAI, thyroid function usually returns to normal within 2-6 months 
and hypothyroidism develops within 4-12 months, or even later (Cooper, 2003). In 
a meta-analysis of 35 studies and 7 241 patients with Graves´ disease treated with 
subtotal or total thyroidectomy, all the patients treated with total thyroidectomy 
became hypothyroid. Of the patients treated with subtotal thyroidectomy, 59.7% 
achieved euthyroidism and 25.6% hypothyroidism (Palit et al., 2000). The patients 
treated with RAI may remain hypo- or hyperthyroid for longer periods of time 
after the treatment compared to the thyroidectomized patients. Thyroidectomy 
offers almost an immediate cure of hyperthyroidism and the treatment with 
levothyroxine is started without delay. This hypothesis is supported by the results 
of a recent comparative study on the time lag to euthyroidism after the treatment 
of hyperthyroidism either with RAI or thyroidectomy (Davis et al., 2018). There 
were 96 patients treated with thyroidectomy and 121 patients treated with RAI in 
this study. The patients treated with thyroidectomy became euthyroid within three 
months after surgery compared to nine months after RAI, and the RAI-treated 
patients needed twice as often adjustments in medication during this time as 
the thyroidectomized patients. The difference in the restoration of euthyroidism 
may partly explain the better prognosis of the patients treated surgically. This is 
supported by the better outcome of the patients treated more effectively with RAI 
(resulting in levothyroxine-treated hypothyroidism) compared to the patients 
treated surgically in this study.
The results indicate that an effective treatment of hyperthyroidism is likely 
to have a major impact on the cardiovascular prognosis of the patients. Similar 
results with a decreased CVD morbidity and mortality of patients developing 
hypothyroidism after treatment with RAI have been reported previously (Flynn 
et al., 2006; Metso, Jaatinen et al., 2007; Boelaert et al., 2013). Furthermore, 
the duration of dysthyroidism, i.e overt or subclinical hyperthyroidism or 
hypothyroidism, was reported to increase overall mortality in a large Danish 
register-based study of TSH measurements in 239 678 individuals. A 9% excess 
overall mortality was detected for each six-month period with low TSH levels. An 
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excess mortality, however, was also associated with elevated TSH, highlighting the 
importance of euthyroidism for the prognosis (Laulund et al., 2014). 
Likewise, a recent paper based on the same Danish register data reported an 
increased risk of mortality in both treated and untreated hyperthyroidism. There 
was an association between the number of periods of low TSH and mortality 
(Lillevang-Johansen et al., 2017). According to the results of this study and the 
previous studies with a long-term follow-up (Franklyn et al., 1991; Hall et al., 
1993; Franklyn et al., 2005; Metso, Jaatinen et al., 2007; Metso et al., 2008) 
changes in the cardiovascular system during the hyperthyroid phase result in 
increased CVD morbidity and also mortality even after restoring euthyroidism. 
The mechanisms of the persistent risk still remain unclear. Based on the current 
literature represented, it seems that the excess morbidity and mortality associated 
with hyperthyroidism seem not to be caused by a specific treatment modality, 
but rather an inability to keep the patients euthyroid. Giesecke et al. presented a 
similar interpretation of the effect of hyperthyroidism per se and not the treatment 
modality on CVD morbidity and mortality, based on their study including 
hyperthyroid patients treated either with RAI or thyroidectomy. They did not, 
however, report the impact of the treatment modality on the cardiovascular 
outcomes in this study (Giesecke et al., 2017).
The patients treated surgically for hyperthyroidism differ from the patients 
treated with RAI in several aspects. The underlying thyroid disease, patient 
preferences, as well as the age and the operative risks of the patient are considered 
when choosing the treatment modality. Most of the hyperthyroid patients have 
been treated with RAI during the past few decades in Finland. Thyroidectomy 
may have been chosen, if the patient had a large goiter with compressive 
symptoms, a suspicion of malignancy, severe eye symptoms of Graves´ disease, or 
hyperthyroidism resistant to antithyroid medication during pregnancy. Due to 
the different patient selection for the different treatment modalities, the treatment 
groups are not totally comparable in a non-randomized, register-based study, and 
there is a possibility of confounding by indication. 
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6.1.3 Cancer incidence and mortality
One of the main results in this study is that the overall cancer incidence was 
not increased in a large cohort of hyperthyroid patients treated either with 
thyroidectomy or with RAI, compared to age- and gender-matched populations, 
and that the treatment modality of hyperthyroidism did not have an effect on 
cancer morbidity or mortality. The result of unchanged cancer incidence contradicts 
with some previous studies (Goldman et al., 1988; Metso, Auvinen et al., 2007; 
Metso, Jaatinen et al., 2007; Hoffman et al., 1982), but is in line with others (Holm 
et al., 1991; Ron et al., 1998). Furthermore, some of our study population treated 
with RAI overlaps with a study population of a study by Metso et al with a result 
of increased cancer incidence (Metso, Auvinen et al., 2007) and mortality (Metso, 
Jaatinen et al., 2007). The study population of Metso et al consisted of patients 
treated with RAI for hyperthyroidism in Tampere University Hospital between 
January 1965 and June 2002. The patients in this more recent study were treated 
between 1986 and 2007 with an overlap of 4,5 years in these cohorts. The possible 
explanations for the differences in cancer incidence in these partly overlapping 
study cohorts are the higher number of patients included in the first cohort (2 793 
patients compared to 1809 patients) and the higher median age of the patients (62 
years compared to 59 years). Furthermore, the first cohort included patients since 
1965 with fewer diagnostic and treatment resources available for cancer, compared 
to the later cohort during the follow-up time. The mean dose of RAI administered, 
however, was comparable in these cohorts (305MBq and 323MBq). 
There has been a significant increase in cancers of some specific sites, even in 
studies reporting unchanged overall outcome to cancer incidence or mortality in 
hyperthyroid patients. An increased incidence of stomach cancer (Hoffman et al., 
1982; Holm et al., 1991; Metso, Auvinen et al., 2007), breast cancer (Goldman 
et al., 1988; Metso, Auvinen et al., 2007), kidney cancer (Metso, Auvinen et al., 
2007; Hieu et al., 2012) and lung cancer (Holm et al., 1991) has been reported. 
These previous studies have mainly included patients treated with RAI for 
hyperthyroidism. Previously, the increased incidence of cancer has been assumed to 
be associated with the oncogenic effects of radiation. Nevertheless, in this present 
study with 70% of patients treated with thyroidectomy, an increase in respiratory 
tract and stomach cancer incidence was detected without association with 
treatment modality. In addition, the median age of the patients was lower (49 vs 
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56–62 y, respectively) compared to previous studies indicating a lower baseline risk 
of cancer and the exposure to RAI (median 259MBq) was lower in the RAI-treated 
group than in most of the previous studies (300–500MBq).
In our study, there was an association between kidney, breast, and respiratory 
tract cancer incidence and nodular thyroid disease. Hyperthyroidism caused 
by nodular disease develops slowly and thus a longer period of subclinical or 
undiagnosed and untreated hyperthyroidism may be more common in nodular 
disease than in Graves´ disease prolonging the exposure to an excess of thyroid 
hormones. There could also be an association between breast cancer and thyroid 
nodularity. Turken et al studied 150 patients with breast cancer and 100 healthy 
controls and found an increased incidence of nodular goiter and higher level 
of thyroid peroxidase autoantibodies (TPO-Ab) in patients with breast cancer 
compared to healthy controls (Turken et al., 2003). In a recent Danish study on 
the etiological subgroups of hyperthyroidism, the patients with a multinodular 
goiter were older compared to patients with Graves’ disease (Brandt et al., 2013a). 
To some extent the association between cancer incidence and nodular goiter could 
be explained by the advanced age of the patients with a nodular goiter as increasing 
age is a known risk factor for cancer. In our study, the patients with a nodular 
thyroid disease were older compared to the patients with Graves´ disease, and 
age increased the risk of cancer by 8% / year. Similarly, breast cancer and thyroid 
disorders are both more prevalent in postmenopausal women, which could be a 
confounding factor. 
An increased risk of specific cancer types, however, was detected compared to 
age- and gender-matched controls, indicating that toxic nodular goiter may be an 
independent risk factor for these cancers or may have some shared risk factors with 
them. There are also shared risk factors for thyroid nodularity and cancer. Thyroid 
nodularity has been associated with iodine deficiency (Laurberg et al., 2006) and, 
interestingly, with the metabolic syndrome (Kir et al., 2018). In a large register-based 
study on 94 555 women, there was a 13% higher risk of breast cancer in women 
with the metabolic syndrome compared to women without the syndrome (Dibaba 
et al., 2018). In another study on postmenopausal women aged 50-79, the risk of 
invasive estrogen- or progesterone-receptor positive breast cancer and breast cancer 
mortality had a strong association with BMI over 35.0 (Neuhouser et al., 2015). 
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6.2 The strengths and limitations of the study and the validity of the data
6.2.1 Enrollment of the patients treated with thyroidectomy
The patients treated with thyroidectomy for hyperthyroidism were identified from 
the HILMO database maintained by the THL. The search for the patients was 
based on the combination of the diagnosis of hyperthyroidism (ICD-codes) and 
the procedure codes for total or subtotal thyroidectomy. The database includes the 
hospitalizations with overnight stay since January 1969 and the procedure codes 
since 1986. The selection of the starting date of this study (1st Jan 1986) was based 
on the availability of the procedure codes. Due to the nationwide registration 
and the specific codes, it was possible to obtain data on all the patients treated for 
thyroidectomy during the study period in Finland. 
The validity of the procedure codes has been addressed in some Finnish 
studies. The procedure codes in HILMO database for CAD between 2007-2014 
covered 84,6% of the procedure codes of PCI and 97,1% for coronary artery 
bypass grafting (CABG) compared to the local register of Kuopio University 
Hospital Heart Center (Heiskanen et al., 2016). However, about one-third of 
the elective procedures were misclassified as non-elective procedures although the 
procedure codes were correct. The procedure codes for multiple trauma patients 
were found to be quite good compared to patient files and the trauma registry of 
Helsinki University Hospital trauma unit (Heinänen et al., 2017). The validity of 
procedure codes for thyroidectomies has not been evaluated. Since thyroidectomy is 
a demanding surgery performed by a few surgeons in Finland, it is quite likely that 
the enrolling of the diagnoses and procedure codes are accurate.
6.2.2 The register of the patients treated with RAI
Information on the patients treated with RAI has been systematically registered 
since 1965 into a computerized register in collaboration with the department of 
nuclear medicine and the department of internal medicine at Tampere University 
Hospital. There is no similar register-based data available from other hospitals in 
Finland. Tampere University Hospital has a catchment population of 500 000 
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(10% of the Finnish population) and it is the only provider on RAI treatment in 
the area ensuring that all the patients treated with RAI are included in the study. 
Information on the etiology of hyperthyroidism, previous surgical treatment, the 
dates and doses of RAI treatments, and the follow-up data on thyroid function 
after the treatment were obtained from the register. Following the RAI treatment, 
the thyroid status of the patients has been monitored by blood samples every 1-3 
months during the first year, and subsequently every 1-3 years.
6.2.3 Cardiovascular diseases
The enrolling of diagnoses to the HILMO database is obligatory in Finland and the 
register has been used since 1969. The variables gathered in the register include date 
of birth, gender, county, hospital ID, dates of admissions and discharges and all the 
diagnoses given. The accuracy of the register was found to vary from satisfactory 
to good in a large study of 32 articles using information from this database and 
comparing it to an external data. Over 95% of the hospital discharges were found 
in the register with positive predictive value varying between 75-99% (Sund, 2012).
In separate studies evaluating the validity of this database during the follow-up 
time of this study, the validity has been found to be fairly good for stroke morbidity 
and mortality (coverage 95% and sensitivity 85-86%) compared to the population-
based FINSTROKE register (Tolonen et al., 2007) and reasonable for CAD 
compared to the FINMONICA/FINAMI data (positive predictive value 90%, 
sensitivity 82% (Pajunen et al., 2005).
Since no data on out-patient visits was available, our study lacks information 
on diseases treated mainly on out-patient visits. Since significant cardiovascular and 
cancer diseases usually require a hospital admission at least for one night at some 
point, the information was evaluated to be sufficient for this study. Furthermore, 
we included the first three ICD-codes for each hospitalization, which increases the 
probability of accessing also for the diseases treated mainly on out-patient visits, 
like hypertension and a stable CAD. 
A randomized study comparing the treatment modalities of hyperthyroidism 
is not possible, since the indications for the treatment modalities differ and many 
of the patients are not eligible for thyroidectomy due to comorbidities affecting 
surgical and anesthetic risk. In this study, however, it was possible to narrow the 
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gap between study groups by adjusting the results for the main clinical variables, 
including age, gender, prior CVDs, and the etiology of hyperthyroidism. Because 
of the register-based nature of this study, the results could not be adjusted 
for the common risk factors of CVDs, including smoking, family history, 
diabetes, hyperlipidemia or medication. Furthermore, the possible relapses of 
hyperthyroidism after thyroid surgery could not be verified due to a lack of data on 
thyroid function tests after thyroidectomy. Neither did we have information on the 
treatment response of the levothyroxine treatment after thyroid surgery, which could 
be a confounding factor in evaluating of the risk of CVDs.
6.2.4 Cancer incidence
The information on cancer diagnoses and mortality was obtained from the 
Finnish Cancer registry, which is a nation-wide, population-based registry. The 
registry was established in 1952 and contains information on most of the cancer 
diagnoses and deaths in Finland since then. The accuracy of the database has been 
evaluated to be excellent (Teppo, Pukkala, & Lehtonen, 1994). Reporting of new 
cancer diagnoses has been obligatory in Finland since 1961 for all physicians, 
hospitals and diagnostic laboratories involved in cancer diagnostics. The aim of 
the Finnish Cancer Registry is to obtain at least three different notifications from 
one cancer: from a physician with the clinical information, from a laboratory with 
the diagnostic data, and finally from Statistics Finland, in case of death caused 
by the cancer. Information is derived from laboratories twice a year digitally and 
the information on cancer deaths is updated yearly by Statistics Finland. The 
accuracy of the information in the Finnish Cancer Registry is dependent on the 
accuracy of the information in announcements received. However, the accuracy 
is improved due to several notifications regarding the same cancer diagnosis. In 
case of conflicting information, the information of the clinical announcement by 
a physician is regarded as the most reliable (Finnish cancer registry, description of 
statistics and their quality.).
Due to the register-based nature of this study, we were not able to adjust the 
risk of cancer for the other common risk factors i.e smoking, obesity, medications, 
family history or for diseases treated mainly in outpatient clinics, such as atrophic 
gastritis. Furthermore, it is unclear, how many of our patients treated with 
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thyroidectomy had a previous treatment with RAI due to the lack of nationwide 
registering of RAI treatments in Finland. 
All of the controls were matched with the patients for age, gender, and county 
of residence at the beginning of the follow-up. Matching for the county adjusted 
for any geographical differences in the analyses comparing the patients and the 
controls. Geographical differences, however, could not be adjusted in the analyses 
comparing the patients treated with thyroidectomy and those treated with RAI. 
Nevertheless, the regional variation in cancer incidence is known to be minor in 
Finland; the ratio of the lowest to the highest age-standardized cancer incidence 
rate among the five university hospital districts is 0.83; SD, 13% (Institute for 
Statistical and Epidemiological Cancer Research. Finnish Cancer Registry). In 
support of no notable bias by geographical differences in the present study, the 
results did not change when only the patients treated in Tampere University 
Hospital were included in the analyses.
6.2.5 Mortality 
The information on the deceased and the causes of death were derived from 
Statistics Finland and the dates of deaths from the Population Register Centre via 
a computerized link between the HILMO database and the other two institutions. 
The information on deaths for cancer was also derived from the Finnish Cancer 
Registry. Statistics Finland has kept the archive of causes of death since 1936. 
The database is updated from the death certificates written by Finnish physicians. 
The information obtained from death certificates is checked and completed by 
information on dates of deaths derived from the Finnish Population Centre which 
ensures that the database covers almost 100% of deaths in Finland (Statistic 
Finland. Quality Description: Causes of death 2017. 2018).
In this study, the underlying cause of death was used. The underlying cause of 
death is derived from the death certificate based on the ICD-code and the written 
diagnosis. If the underlying cause of death is unclear based on this information, 
the underlying cause of death is decided by the verbal clinical information given 
on the death certificate or the physician is asked for additional information, which 
makes the enrolling of the causes of death very accurate (Statistic Finland. Quality 
Description: Causes of death 2017. 2018). Furthermore, when the mortality of 
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the controls of the patients treated with thyroidectomy and was compared to the 
controls of the RAI-treated patients in this study, the ratio of the mortality rates in 
this analysis was close to 1.00 indicating no difference in mortality between these 
two control groups, which both represent the general Finnish population.  
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SUMMARY AND CONCLUSIONS
Several studies on cardiovascular and cancer outcomes after treated hyperthyroidism 
have been published during the past 40 years. The general outcome in these studies 
has been an increased cardiovascular and cancer morbidity associated with treated 
hyperthyroidism. There are also results indicating an increased CVD and cancer 
mortality. 
The primary aim of this study was to clarify the possible reasons for the 
increased CVD and cancer morbidity and mortality associated with previously 
treated hyperthyroidism. The hypothesis at the beginning of the study was that the 
increased risk of CVDs and cancer is not due to the treatment of hyperthyroidism, 
but to the disease itself. By studying patients treated either with RAI or with 
thyroidectomy, it was possible to analyze the possible effect of the treatment 
modality on the increased morbidity. 
Prior to the present study, no studies comparing the long-term effects of 
different treatment modalities for hyperthyroidism had been published. In this 
large-scale, comparative cohort study of hyperthyroid patients, the long-term 
consequences of hyperthyroidism and its treatment modalities were studied. A 
significant increase in cardiovascular morbidity and mortality was detected in 
patients with hyperthyroidism. The increased risk for CVDs was attenuated by 
both the treatment modalities studied. Thyroidectomy was more beneficial in 
decreasing the risk of cardiovascular morbidity and mortality in hyperthyroid 
patients than treatment with RAI, and the patients treated with RAI had twice 
as high CVD mortality rates as the patients treated with thyroidectomy. The 
patients who developed hypothyroidism after the treatment with RAI, however, 
had a similar CVD morbidity and an even lower CVD mortality than the patients 
treated with thyroidectomy. After the treatment of hyperthyroidism, there was no 
significant increase in cancer incidence overall in hyperthyroid patients, compared 
to the general population. Nevertheless, an increased risk of gastric and respiratory 
tract cancers in all the hyperthyroid patients and an increased risk of kidney, breast, 
and respiratory tract cancers in the patients with a nodular thyroid disease was 
detected. The treatment modality (RAI or thyroidectomy), however, did not affect 
the risk of cancer. 
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In conclusion, hyperthyroidism per se seems to increase cardiovascular 
morbidity, regardless of the treatment modality used. The incidence of some types 
of cancer is associated with hyperthyroidism, probably due to shared risk factors. 
Most importantly, the risk of CVDs can be decreased by a timely diagnosis and 
effective treatment of hyperthyroidism. Despite the treatment modality, all the 
patients with previous hyperthyroidism should be considered as high-risk patients 
regarding future CVDs and some cancer types. An active follow-up for other risk 
factors and for new cardiovascular symptoms of previously hyperthyroid patients is 
warranted. Furthermore, the results underline the importance of an immediate and 
efficient management of hyperthyroidism, to improve the long-term prognosis of 
hyperthyroid patients.
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Summary
Objective Previous studies suggest that patients with hyperthy-
roidism remain at an increased risk of cardiovascular morbidity
even after restoring euthyroidism. The mechanisms of the
increased risk and its dependency on the different treatment
modalities of hyperthyroidism remain unclear. The aim of this
long-term follow-up study was to compare the rate of hospital-
izations for cardiovascular causes and the mortality in hyperthy-
roid patients treated surgically with an age- and gender-matched
reference population.
Patients and Measurements A population-based cohort study
was conducted among 4334 hyperthyroid patients (median age
46 years) treated with thyroidectomy in 1986–2007 in Finland
and among 12 991 reference subjects. Firstly, the hospitalizations
due to cardiovascular diseases (CVD) were analysed until thy-
roidectomy. Secondly, the hazard ratios for any new hospitaliza-
tion due to CVDs after the thyroidectomy were calculated in
Cox regression analysis adjusted with the prevalent CVDs at the
time of thyroidectomy.
Results The risk of hospitalization due to all CVDs started to
increase already 5 years before the thyroidectomy, and by the
time of the operation, it was 50% higher in the hyperthyroid
patients compared to the controls (P < 0001). After the thy-
roidectomy, the hospitalizations due to all CVDs (HR 115),
hypertension (HR 123), heart failure (HR 117) and valvular
diseases or cardiomyopathies (HR 155) remained more frequent
among the patients than among the controls for 20 years after
thyroidectomy. The increased morbidity was not clearly related
to the aetiology of hyperthyroidism. Despite the increased CVD
morbidity among the patients, there was no difference in cardio-
vascular mortality.
Conclusions The present study shows that hyperthyroidism
increases the risk of hospitalization due to CVDs and the risk is
sustained up to two decades after effective surgical treatment.
However, there was no excess CVD mortality in the middle-aged
patient cohort studied.
(Received 9 June 2013; returned for revision 3 July 2013; ﬁnally
revised 30 September 2013; accepted 27 October 2013)
Introduction
Hyperthyroidism is a common disease, with a prevalence of
approximately 25% among women and 06% in men.1 Surgical
treatment of hyperthyroidism is considered if a patient has a
large goitre with compressive symptoms, a suspicion of malig-
nancy or hyperthyroidism with severe eye symptoms of Graves’
disease and during pregnancy in severe hyperthyroidism resistant
to antithyroid medication.2 Subtotal thyroidectomy was the
standard treatment for hyperthyroidism in the early part of the
twentieth century,3 but nowadays total thyroidectomy is increas-
ingly recommended to reduce thyroid autoimmunity and the
risk of relapsing hyperthyroidism, especially in patients with
Graves′ ophthalmopathy.4,5 Other forms of treatment, that is,
long-term antithyroid medication and radioiodine (RAI) ther-
apy, are commonly used for the treatment of hyperthyroidism.
An immediate relief of hyperthyroidism is an advantage of sur-
gery over other treatment modalities. Low complication rates
have been reported, but their incidence depends largely on the
skills and the experience of the surgeon.6 The most important
complications are permanent hypoparathyroidism and recurrent
laryngeal nerve damage in 07–3% of the patients.6 Transient
hypocalcaemia, bleeding and infection are also potential compli-
cations of thyroid surgery.7
Hyperthyroidism has previously been regarded as a reversible
disorder without persistent consequences, when treated effec-
tively. However, a long-term follow-up study revealed an
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increased cardiovascular morbidity persisting for decades after
RAI treatment of hyperthyroidism, compared with the general
population.8 Cardiovascular mortality has also been found to
increase after treatment with RAI for hyperthyroidism.9–12 Like-
wise, increased long-term cardiovascular morbidity has been
reported in patients treated with antithyroid therapy for hyper-
thyroidism, despite normalized thyroid hormone levels.13 In a
recently published study comparing antithyroid medication and
RAI, the mortality rates were higher than expected during the
periods of thionamide treatment for hyperthyroidism and after
less intensive treatment with RAI (not resulting in hypothyroid-
ism), but not after intensive treatment with RAI, resulting in
hypothyroidism and T4 replacement therapy.
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To date, no long-term studies have been published on the
incidence of cardiovascular diseases (CVD) in relation to total
or subtotal thyroidectomy for hyperthyroidism. Thus, the pur-
pose of the present study was to assess the rate of hospitalization
and mortality due to CVD among hyperthyroid patients treated
with thyroid surgery in comparison with a matched reference
population.
Subjects and methods
The patients operated for hyperthyroidism were identiﬁed from
the nationwide Hospital Discharge Registry (HILMO) main-
tained by the National Institute of Health and Welfare (THL)
based on both the diagnosis for hyperthyroidism (International
Classiﬁcation of Diseases, 8th, 9th and 10th revisions, codes 242
and E05) and the procedure codes for total or subtotal thyroid-
ectomy (NCSP, Nordic Classiﬁcation of Surgical Procedure
codes 2504, 2505 and 2506 or BAA25, BAA40, BAA50 and
BAA60 for total or subtotal thyroidectomy). The enrolling of
diagnoses to the HILMO database is obligatory in Finland, and
its completeness and accuracy has been found to vary from sat-
isfactory to very good.15 The database includes the hospitaliza-
tions and causes of hospitalization (hospital admission requiring
an overnight stay) of the Finnish residents since January 1969,
and the procedure codes since 1986. Our follow-up covers
patients treated with total or subtotal thyroidectomy for hyper-
thyroidism between the years 1986 and 2007. Due to the nation-
wide registration and the speciﬁc codes, the case series
represents all incident cases of hyperthyroidism treated with
total or subtotal thyroidectomy in Finland during the follow-up
period.
A reference group was formed by randomly choosing three
age- (6 months) and gender-matched control subjects for each
patient from the comprehensive national Population Register
Centre. Three controls were chosen to optimize the sample size
and the statistical power of the study. The control subject had
to be alive at the time the patient was operated and reside in the
same county. The persons were excluded if they were already in
the group of patients.
The lifetime causes of hospitalization, as well as the date of hos-
pital admission were obtained from the HILMO, with determinis-
tic record linkage based on the unique personal identiﬁcation
number assigned to all the residents of Finland. Both the primary
and secondary diagnoses recorded at discharge from the hospital
were used in the analysis. The diagnoses have been coded accord-
ing to the Finnish version of the 8th revision of the International
Classiﬁcation of Diseases (ICD-8) in 1986, ICD-9 between 1986
and 1995, and the Finnish version of ICD-10 thereafter. A conver-
sion between the different versions was made, and the causes of
hospitalization were classiﬁed into eight major cardiovascular
groups, which were analysed separately: hypertension; coronary
artery disease; diseases of the pulmonary circulation; arrhythmias;
heart failure; cerebrovascular diseases; diseases of arteries and
veins (including for example arteriosclerosis obliterans, aortic
aneurysms and dissections and thrombosis of both arteries and
veins), and valvular diseases and cardiomyopathies. Within the
group of arrhythmias, atrial ﬁbrillation (AF) was studied
separately.
The causes of death of the patients and controls were obtained
from the Statistics Finland using a computerized record linkage.
The dates and causes of death of all deceased citizens certiﬁed by a
physician are included in this register since 1971. The causes of
death have been coded according to the International Classiﬁca-
tion of Diseases (ICD). For mortality analysis, we used the under-
lying cause of death. The dates of death and emigration of the
patients and the controls were obtained from the Population
Registration Centre using computerized record linkage.
Firstly, the difference in the rate of hospitalizations between
the patients and the controls was illustrated by Kaplan–Meier
curve beginning 10 years before the thyroidectomy in the whole
study population. Furthermore, Kaplan–Meier curves were esti-
mated separately in different aetiological subgroups of patients
and by age group (under 20, 20–40, 40–60 and over 60 years)
using only the corresponding controls. The incidence of ﬁrst
hospitalization due to different CVDs preceding thyroidectomy
was analysed until the date of thyroidectomy.
Secondly, the effect of thyroidectomy on the hospitalizations
due to CVD was analysed by counting the new hospitalizations
due to CVDs after the treatment of hyperthyroidism with fol-
low-up starting at the date of the surgery for the patients and
for the same date for the matched controls. The follow-up ended
on the date of the ﬁrst hospitalization due to CVD, the date of
death, emigration or the common closing date (31 May, 2009),
whichever occurred ﬁrst (Fig. 1).
The study was undertaken in accordance with the Declaration
of Helsinki. No informed consent could be obtained from the
patients, because of the large number of participants. The ethics
committee of the Pirkanmaa Hospital District reviewed the
study protocol. The National Institute of Health and Welfare
(THL) gave a permission to use data from the Hospital
Discharge Registry.
Statistical analysis
We used the statistical software Stata for Windows version 8.2
(StataCorp, College Station, TX, USA) to calculate the hospital-
ization rates for various diseases. Cox regression analyses were
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performed using IBM SPSS Statistics for Windows, version 19.0
(IBM Corp. Released 2010. Armonk, NY, USA). A two-sided
P-value of less than 005 was considered statistically signiﬁcant.
Hospitalization rates due to CVDs beginning 10 years before
thyroidectomy were illustrated with Kaplan–Meier curves in the
patients and the controls. Conditional logistic regression model
was ﬁtted to assess the cumulative risk of hospitalization due to
different CVDs until the date of thyroidectomy. The distribution
of the aetiological diagnoses between men and women or
between different age groups was analysed using chi-square test.
To estimate the CVD morbidity after the thyroidectomy, two
different kinds of Cox regression analyses were performed. The
ﬁrst analysis included all the patients and the controls and was
used to estimate the hazard ratios (patients vs. controls) for
CVD hospitalizations after the thyroidectomy. Previous hospital-
ization due to the given CVD was used as a covariate in this
analysis to adjust for differences in CVD morbidity between the
groups prior to the time of thyroidectomy.
Another Cox regression analysis was performed only on the
patients to evaluate the effect of age, gender, the type of surgery
and the aetiology of hyperthyroidism on CVD morbidity after
the thyroidectomy. The covariates used were age at the time of
thyroidectomy, gender, the type of surgery (total or subtotal)
and the aetiology of hyperthyroidism (Graves′ disease,
multinodular goitre, toxic adenoma, other). To adjust for any
differences in prevalent CVD morbidity, previous CVD hospital-
ization (prior to the thyroidectomy) was used as a covariate, as
well.
In addition to the analyses of the whole study population, we
analysed the time varying component of CVD morbidity by
dividing the study cohort in two subgroups, based on the year
of thyroidectomy (1986–1995, coded by ICD-8 and ICD-9, or
1996–2007, coded by ICD-10).
Mortality rates were calculated by dividing the number of the
deceased subjects with the corresponding person-years. The
ratio of the death rates after the thyroidectomy in the patients
treated surgically for hyperthyroidism and in the age- and sex-
matched control group was estimated by the Mantel–Haenszel
method.
Results
A total of 4334 patients were treated for hyperthyroidism with
total or subtotal thyroidectomy between January 1986 and
December 2007 in Finland. Eighty-six per cent (n = 3719) of the
patients were women and 14% (n = 615) were men. The median
age of the patients and the reference group at the time of sur-
gery was 46 (interquartile range 33–59) years in the whole
group, 48 (interquartile range 33–61) years in men and 46 (in-
terquartile range 339–59) years in women. Four per cent of the
patients (179 patients) were under 20 years of age at the time of
the operation. Twelve per cent (n = 497) of the patients and
11% (n = 1421) of the controls deceased during the follow-up
time and a total of 146 subjects emigrated from Finland (Fig. 1).
There were no statistically signiﬁcant differences in total mortal-
ity or emigration rates between the groups.
The risk of hospital admission due to any CVD increased
among both the patients and the controls during the whole fol-
low-up, and the difference between the two groups increased up
to the time of thyroidectomy, becoming statistically signiﬁcant
already 5 years before the thyroidectomy (OR 115, 95% CI
104–128) [Figs 2 (panel a) and 3]. Until the thyroidectomy, the
patients had a 50% increase in the risk of hospitalization due to
any CVD, compared to the controls (OR 150, 95% CI 137–
164) (Table 1). The most frequent subgroup of CVD associated
with the increased hospitalization was hypertension. The differ-
ence in hospitalizations with hypertension between the patients
and the controls increased prior to the thyroidectomy (Fig 2,
Panel b), and the hospitalization rate was twice as high in the
patients as among the controls by the time of the operation (OR
205, 95% CI 167–251) (Table 1). The second most frequent
indication for hospitalization was arrhythmias, of which AF was
the most common diagnosis (81% of arrhythmias). The differ-
ence in the rates of hospitalization due to AF increased towards
the time of thyroidectomy (Fig 2, Panel c), the rate being almost
ﬁve times higher in the patients at the time of thyroidectomy
(OR 460, 95% CI 372–567). There were no substantial differ-
ences in the hospitalization rates due to ischaemic heart disease
(including acute myocardial infarctions), diseases of other
Fig. 1 Number of the patients treated with
thyroidectomy for hyperthyroidism and the age-
and gender-speciﬁc control group.
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arteries and veins, cerebrovascular diseases or diseases of pulmo-
nary circulation between the patients and the controls before the
thyroidectomy. However, the risk of hospitalization due to heart
failure by the time of thyroidectomy was almost twofold (OR
192, 95% CI 122–300), and the risk of valvular diseases or car-
diomyopathies was 57% higher (OR 157, 95% CI 098–251)
among the patients compared to the reference group (Table 1).
After the thyroidectomy, the risk of new hospitalization due
to any CVD was still signiﬁcantly higher among the patients,
when adjusted for hospitalization preceding thyroidectomy (HR
115, 95% CI 106–124). The incidence of new hospitalizations
due to hypertension (HR 123, 95% CI 108–141), arrhythmias
(HR 125, 95% CI 107–147), heart failure (HR 117, 95% CI
101–150) and valvular diseases and cardiomyopathies (HR
155, 95% CI 117–204) was signiﬁcantly higher in the patients,
when adjusted for hospitalization due to the given disease prior
to the operation. Furthermore, the risk of new hospitalization
due to AF tended to remain higher in the patients than in the
controls, although the difference was not statistically signiﬁcant
(HR 115, 95% CI 096–139) (Table 2).
The most common cause of hyperthyroidism among the
operated patients was Graves′ disease (48% of the patients).
Hyperthyroidism was caused by a multinodular goitre in 33% of
the patients, and 6% had a toxic adenoma. Thirteen per cent of
the patients had a diagnosis of nonspeciﬁed hyperthyroidism and
was classiﬁed as ‘Other’. Twenty-six patients (06%) had subclini-
cal hyperthyroidism, and they were analysed as a separate group.
The most common aetiological diagnosis in patients under
40 years of age was Graves′ disease and in patients older than
40 years multinodular goitre (P < 0001). The distribution of the
aetiological diagnoses was similar between men and women.
The risk of hospitalization due to any CVD among the
patients was not yet increased 10 years before the surgery, com-
pared with the corresponding controls, but the risk began to
increase several years before the thyroidectomy, regardless of the
aetiology of hyperthyroidism (Fig. 2, Panels d-e). In patients
with multinodular goitre, the cumulative risk up to the thyroid-
ectomy was 56% higher compared with their controls (OR 156,
95% CI 136–180) and in patients with Graves′ disease 32%
higher (OR 132, 95% 113–154).
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Fig. 2 Cumulative hospitalization rates due to different cardiovascular diseases (a-c) 10 years before and more than 20 years after thyroidectomy in all
patients treated surgically for hyperthyroidism (a-c) and in different ethiologies of hyperthyroidism (d-e), compared with the age- and sex-matched
control group.
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However, in a Cox regression analysis on hospitalizations after
the thyroidectomy including only the patients, male gender (HR
123, 95% CI 105–146), age at the time of surgery (HR 106, 95%
CI 106–107/year) and hospitalization due to CVD before surgery
(HR 219, 95% CI 191–250) predicted hospitalization due to
CVD after surgery, while the surgical technique (subtotal or total
thyroidectomy) or the aetiology of hyperthyroidism did not).
When the time varying component of CVD morbidity was
analysed by dividing the study cohort in two subgroups by the
year of thyroidectomy (1986–1995 and 1996–2007), hospitaliza-
tion due to any CVD after the thyroidectomy was increased in
both patient groups vs the respective controls. The risk of CVD
hospitalization was 12% higher in the patients operated during
1986–1995 compared with their controls (RR 112, 95% CI
101–124), and the patients treated during 1996–2007 had a
20% higher risk than their controls (RR 120, 95% CI 104–
140).
A total of 114% (n = 497) of the patients and 109%
(n = 1421) of the controls deceased during the follow-up. Mor-
tality from CVDs was not increased among the patients com-
pared to the controls (RR 091, 95% CI 077–107). The
mortality rates did not differ between the patients and the con-
trols, when analysed separately in men and women, in different
subgroups of CVDs, or in the aetiological subgroups of hyper-
thyroidism (data not shown).
Discussion
The present study is the ﬁrst one to show that patients treated
with total or subtotal thyroidectomy for hyperthyroidism have
an increased risk of hospitalizations due to CVDs already before
the treatment and the risk is sustained after thyroidectomy. The
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Fig. 3 Cumulative hospitalization rates due to all
cardiovascular diseases 10 years before and more
than 20 years after thyroidectomy in the different
age groups of patients (a-d) treated surgically for
hyperthyroidism, compared with the age- and sex-
matched control group.
Table 1. The odds ratios for cumulative hospitalization rates prior to
the thyroidectomy due to different cardiovascular diseases in patients
treated with thyroidectomy for hyperthyroidism, compared with the
age- and sex-matched controls
Cardiovascular disease
Patients vs Controls
Odds ratio
(95% CI) P value
All cardiovascular diseases 150 (137–164) <0001
Hypertension 205 (167–251) <0001
All arrhythmias 393 (320–481) <0001
Atrial ﬁbrillation 460 (372–567) <0001
Diseases of arteries and veins 110 (095–128) 0209
Coronary disease 080 (056–115) 0413
Cerebrovascular diseases 112 (095–132) 0227
Heart failure 192 (122–300) 0005
Valvular diseases and
cardiomyopathies*
157 (098–251) 0060
Diseases of pulmonary arteries 156 (080–304) 0211
*Nonbacterial endo-, peri- and myocardial diseases, including valvular
diseases and cardiomyopathy.
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increased risk of hospitalization due to CVD is mostly related to
hypertension, AF, heart failure, and valvular diseases and cardio-
myopathies. However, the risk of hospitalization due to diseases
affecting coronary arteries, other arteries or veins, or pulmonary
circulation is not increased. The results are in line with the
previous ﬁndings regarding patients treated with RAI for hyper-
thyroidism, although the patients selected for surgery were
younger (median age 46 years in the present study) than those
treated with RAI. In our previous study on patients treated with
RAI for hyperthyroidism, the median age at the time of treat-
ment was 62 years8 and in other similar studies on RAI-treated
patients the median ages have been between 57 and
62 years.9,10,16 Thyroid surgery is an effective treatment for
hyperthyroidism with a high and predictable cure rate.17,18 Our
results indicate that hyperthyroidism increases cardiovascular
morbidity even in relatively young patients. Importantly, the
cardiovascular changes caused by hyperthyroidism are not totally
and immediately reversed by thyroidectomy, neither a total nor
a subtotal one.
Despite the increased risk of hospital admission due to CVD
before thyroidectomy and the sustained risk afterwards, there
was no difference in CVD mortality between the patients and
their controls. A recent meta-analysis on mortality after treated
hyperthyroidism, including seven studies with 31 138 patients,
showed a 20% increase in all-cause mortality.19 In these studies,
the patients were treated mainly with RAI. In our study, the
statistical power and the length of the follow-up may be insufﬁ-
cient for detecting a slightly increased mortality in the relatively
young group of patients (median age at thyroidectomy
46 years), but the equal mortality may also be due to the effec-
tive treatment of hyperthyroidism with thyroidectomy. Based on
a recent study from Boelaert et al., an effective treatment with
RAI (resulting in hypothyroidism) reduces mortality compared
to an ineffective RAI treatment or treatment with thionamides.15
In our study, the patients with hyperthyroidism had an
increased risk of hospitalization related to hypertension already
years before thyroidectomy, and the risk was sustained after-
wards. In hyperthyroidism, increased preload, heart rate and car-
diac output may lead to hypertension and left ventricular
hypertrophy.20 Left ventricular hypertrophy was a complication
of long-term hypertension and an independent risk factor for
cardiovascular morbidity and mortality in the Framingham
Heart Study.21 However, hyperthyroidism reduces peripheral
vascular resistance,22 and in previous studies, the association
between elevated blood pressure and hyperthyroidism has been
less convincing. Elevated blood pressure has been more prevalent
in subclinical hypothyroidism than in subclinical hyperthyroid-
ism.23 Hypertension is rarely the only reason for hospitalization,
but it is probably associated with other cardiovascular diagnoses,
which may have been the primary reason for hospitalization in
our study, where both the primary and the secondary diagnoses
were analysed. The present results suggest that hyperthyroidism
may predispose to a permanent rise in blood pressure, with
associated cardiovascular morbidity. On the other hand, elevated
blood pressure may also reﬂect inadequate L-Thyroxine treat-
ment after the thyroidectomy.
The hyperthyroid patients in our study had a remarkably high
risk of arrhythmias, especially AF, before thyroidectomy, but the
thyroidectomy seemed to slow down the rapid increase in the
incidence of new arrhythmias. However, the risk of new arrhyth-
mias remained higher after treatment of hyperthyroidism with
thyroidectomy, when adjusted for the prior arrhythmias at the
time of thyroidectomy. This is in line with previous studies.24
The increased risk of hospitalization due to CVDs seen already
years before the thyroidectomy might be caused by undiagnosed
or ineffectively treated hyperthyroidism before the surgery. In
fact, a recently published Danish study showed that the risk of
AF is associated with thyroid function, with a low risk in hypo-
thyroidism and a high risk in hyperthyroidism. There was also
an association between the TSH level and the risk of AF across
the spectrum of subclinical thyroid disease.25 Hyperthyroidism
shortens the atrial refractory period by altering cell membrane
functions26 and also seems to increase supraventricular ectopic
activity in hyperthyroid patients without previous heart dis-
ease.27 Both these factors are triggers for AF, and AF feeds itself
by altering the electrical28 and mechanical functions of the
atria29 and also changes the atrial structure by causing ﬁbrosis
in the heart muscle.30,31 This remodelling of the atria prolongs
arrhythmias and predisposes to relapses. Patients with hyperthy-
roidism are susceptible to AF and an episode of AF predisposes
to recurrent AF. This combined effect of AF and hyperthyroid-
ism on the heart muscle may explain the persisted risk of AF
among the patients with treated hyperthyroidism. Based on our
results, treatment of hyperthyroidism with thyroidectomy seems
to decrease the incidence of AF signiﬁcantly, but the risk still
remains higher in the patients than in the controls.
Table 2. The number of hospitalizations and hazard ratios (HR) for
hospitalization rates due to different cardiovascular diseases after the
thyroidectomy in patients treated with thyroidectomy for hyperthyroidism,
compared with the age- and sex-matched control group, and adjusted for
the prevalent CVDs prior to the thyroidectomy
Cardiovascular disease
Hospitalizations Patients vs controls
Patients Controls Hazard ratio P value
All cardiovascular
diseases
1000 2658 115 (106–124) 0001
Hypertension 386 924 123 (108–141) 0002
All arrhythmias 335 678 125 (107–147) 0005
Atrial ﬁbrillation 262 527 115 (096–139) 0139
Diseases of arteries
and veins
330 893 109 (096–125) 0185
Coronary disease 304 878 103 (087–119) 0727
Cerebrovascular
diseases
194 521 119 (099–141) 0057
Heart failure 169 432 117 (101–150) 0039
Valvular diseases and
cardiomyopathies*
87 170 155 (117–204) 0002
Diseases of pulmonary
arteries
33 126 078 (053–115) 0211
*Nonbacterial endo-, peri- and myocardial diseases, including valvular
diseases and cardiomyopathy.
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The risk of hospitalization due to heart failure and valvular dis-
eases or cardiomyopathies after surgically treated hyperthyroidism
was increased before the thyroidectomy and remained increased
after surgical treatment of hyperthyroidism. Hyperthyroidism
increases cardiac preload, body ﬂuid volume and heart rate and
affects both the systolic and the diastolic function of the heart.22
Overt hyperthyroidism may thereby worsen the symptoms of an
underlying, undiagnosed heart disease, leading to an earlier hospi-
talization and diagnosis of the heart disease, compared to an
euthyroid person with the same undiagnosed heart disease.
When analysed separately, the cumulative risk ratio of hospi-
talization due to CVDs seemed to be slightly higher in the
patients with a toxic nodular goitre than in those with Graves′
disease before the thyroidectomy (OR 156 vs 132). After the
thyroidectomy, the different aetiological subgroups did not have
an impact on the CVD hospitalization risk in a multivariate
analysis. Hyperthyroidism caused by multinodular goitre devel-
ops slowly and a prolonged period of subclinical or undiagnosed
and untreated hyperthyroidism may be more common in
patients with a multinodular goitre than in those with Graves′
disease. However, thyroidectomy seemed to reduce the incidence
of CVD in both aetiological subgroups, and their long-term
prognosis did not differ.
Subtotal thyroidectomy was the standard surgical treatment
for hyperthyroidism in Finland until the end of the 20th cen-
tury, but later on total thyroidectomy has been the preferred
technique. In 1986, only three per cent of the thyroidectomies
were total, but the proportion of total thyroidectomies out of all
operations increased up to 80% by the end of the study period
in 2007. The proportion of subtotal operations was higher in all
the age groups and aetiological groups in our study. In the mul-
tivariate analysis, the type of thyroidectomy did not have an
effect on the risk of hospitalization due to any CVD.
The risk of CVD hospitalization was slightly higher in the
patients thyroidectomized during 1996–2007 than in those trea-
ted during 1986–1995. The diagnostic and treatment strategies
of CVDs have developed remarkably during the follow-up time,
and the slightly higher risk of CVD hospitalization in the
patients of the latter time period is probably explained by
improved diagnostic methods and more intensive treatment
strategies.
The strengths of our study are the relatively long follow-up
and a large cohort of patients, representing all the incident cases
of hyperthyroidism treated with thyroidectomy in Finland dur-
ing the follow-up period, due to the nationwide registration and
the speciﬁc diagnosis and procedure codes. Furthermore, we
were able to analyse the cardiovascular morbidity in the different
aetiological subgroups of hyperthyroidism. However, there are
some limitations to this study. The results are based on register
data and dependent on the correct recording of the diagnoses.
However, several assessments consistently indicate high com-
pleteness and reliability of the Finnish Hospital Discharge Regis-
ter for CVDs.32,33 Owing to the nature of our study, we were
not able to adjust the results for the common risk factors of
CVD, such as smoking, hypercholesterolaemia, diabetes or fam-
ily history. Smoking is a common confounding factor in epide-
miological studies and may also be a common risk factor
underlying both hyperthyroidism and CVD.34 Hence, its effect
may result in overestimation of the CVD risk caused by hyper-
thyroidism.
The lack of information on the time of the beginning of
hyperthyroidism based on TSH and T4 values is a major limita-
tion of our study. The increased risk of hospitalization due to
CVD seen already years before the thyroidectomy might be
caused by undiagnosed or ineffectively treated hyperthyroidism
before the surgery. Furthermore, in the absence of data on thy-
roid function tests, we could not assess the severity of hyperthy-
roidism. On the other hand, hyperthyroidism may be caused by
iodine-containing drugs used in CVD, like amiodarone or radio-
logical contrast media. Interestingly, a recent twin study showed
that patients with hyperthyroidism may have shared genetic sus-
ceptibility to both cardiovascular morbidity and hyperthyroid-
ism, and their cardiovascular system might be affected already
before the emergence of hyperthyroidism.35 Due to the registry-
based setting of the study, we do not have information on the
duration of hyperthyroidism before the thyroidectomy, on the
rate of relapses of hyperthyroidism, or on the success or failure
of the L-thyroxine treatment after thyroid surgery. Both under-
and overtreatment of hypothyroidism could increase the risk of
CVD after thyroid surgery. However, there is a strict follow-up
of the thyroid function after thyroidectomy in Finland, and any
relapses of hyperthyroidism are treated with RAI, medical treat-
ment or reoperation without delay.
In conclusion, hyperthyroidism seems to have deleterious
effects on the cardiovascular system even years before the diag-
nosis and the effects persist still after deﬁnitive treatment with
surgery. Further prospective, controlled studies are warranted to
resolve, whether the long-term effects of hyperthyroidism differ
depending on its treatment modality.
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Cardiovascular Morbidity and Mortality After
Treatment of Hyperthyroidism with Either
Radioactive Iodine or Thyroidectomy
Essi Ryo¨di,1,2 Saara Metso,2,3 Heini Huhtala,4 Matti Va¨lima¨ki,5 Anssi Auvinen,4 and Pia Jaatinen2,3,6
Background: Hyperthyroid patients remain at an increased risk of cardiovascular diseases (CVDs) after re-
storing euthyroidism. The impact of the different treatment modalities of hyperthyroidism on future CVD risk
remains unclear. The aims of this study were to assess cardiovascular morbidity and mortality in hyperthy-
roidism before and after treatment, and to compare the effects of two different treatment modalities: radioactive
iodine (RAI) and thyroid surgery.
Methods: A comparative cohort study was conducted among 6148 hyperthyroid patients treated with either RAI
or thyroidectomy and 18,432 age- and sex-matched controls. First, hospitalizations due to CVDs prior to the
treatment were analyzed. Second, the hazard ratios (HR) for any new hospitalization and mortality due to CVDs
after treatment were estimated among all the hyperthyroid patients compared to the age- and sex-matched
controls and also in the RAI-treated patients compared to the thyroidectomy-treated patients. The results were
adjusted for prevalent CVDs at the time of treatment.
Results: Before treatment for hyperthyroidism, hospitalizations due to all CVDs were more common in the
hyperthyroid patients compared to the controls (odds ratio= 1.61 [conﬁdence interval (CI) 1.49–1.73]). During
the post-treatment follow-up, hospitalizations due to CVDs remained more frequent among the patients
(HR= 1.15 [CI 1.09–1.21]), but there was no difference in CVD mortality (HR= 0.93 [CI 0.84–1.03]). Com-
pared to the patients treated with thyroidectomy, the RAI-treated patients had a higher risk of hospitalization
due to all CVDs (HR= 1.17), atrial ﬁbrillation (HR= 1.28), as well as a higher CVD mortality rate (HR= 2.56).
Yet, treatment with RAI resulting in hypothyroidism was not associated with increased CVD morbidity
compared to thyroidectomy.
Conclusions: Hyperthyroidism increases the risk of CVD-related hospitalization, and the risk is sustained for up
to two decades after treatment with RAI or surgery. Hyperthyroid patients treated with RAI remain at a higher
CVD risk compared to patients treated with thyroidectomy. Hypothyroidism during follow-up, however, pre-
dicts better cardiovascular outcomes.
Keywords: hyperthyroidism, morbidity, mortality, thyroidectomy, RAI therapy
Introduction
Hyperthyroidism is associated with increased car-diovascular morbidity and mortality, which are not
completely reversed by the common treatmentmodalities (1–5).
Increased cardiovascular morbidity after treatment of hy-
perthyroidism with radioactive iodine (RAI) has been re-
ported in several previous long-term follow-up studies
(2,6,7). In a previous study of 4334 hyperthyroid patients
treated with thyroidectomy, the risk of hospitalization due to
cardiovascular diseases (CVDs) remained higher among the
patients than among the controls for 20 years after thyroid-
ectomy (1). Increased long-term cardiovascular morbidity
has also been reported in patients treated with antithyroid
therapy for hyperthyroidism, despite normalized thyroid
hormone levels (8).
Previous studies have also shown increased cardiovascu-
lar mortality after treatment with RAI for hyperthyroidism
1Heart Center Co.; 2Department of Internal Medicine; 3Faculty of Medicine and Life Sciences; 4Faculty of Social Sciences; Tampere
University Hospital, Tampere, Finland.
5Division of Endocrinology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland.
6Division of Internal Medicine, Seina¨joki Central Hospital, Seina¨joki, Finland.
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(3–5,8) but not after thyroidectomy (1). In a recently pub-
lished study comparing antithyroid medication and RAI, the
mortality rates were increased during the periods of thio-
namide treatment for hyperthyroidism and after less inten-
sive treatment with RAI (not resulting in hypothyroidism).
However, after intensive treatment with RAI (resulting in
hypothyroidism and thyroxine replacement therapy), the
mortality rates did not differ between the patients and the
controls (9).
Cardiovascular and cancer morbidity and mortality of
patients treated with thyroidectomy and patients treated with
RAI for hyperthyroidism have been reported previously
(1,2,5,10). In the present work, those analyses are extended
by comparing cardiovascular morbidity before and after the
treatment of hyperthyroidism either with RAI or with thy-
roidectomy, and the impact of the treatment modalities and of
the treatment outcomes (hypothyroidism or not) on cardio-
vascular mortality is studied after hyperthyroidism has been
treated.
Methods
For this retrospective, register-based study, two groups of
patients treated previously for hyperthyroidism were identi-
ﬁed. The ﬁrst group consisted of all the patients treated with
thyroidectomy for hyperthyroidism in Finland in 1986–2007
(n = 4334). The patients were identiﬁed based on the proce-
dure codes and International Classiﬁcation of Diseases (ICD)
codes from the nationwide Hospital Discharge Registry
(HILMO) maintained by the National Institute for Health and
Welfare, as previously reported (1). For thyroidectomized
patients, the etiology of hyperthyroidism was obtained from
the HILMO database. Follow-up data on thyroid status after
the treatment were not available for the patients treated with
thyroidectomy.
The second group consisted of the patients treated with
RAI for hyperthyroidism during 1986–2007 at Tampere
University Hospital (n = 1814). It was only possible to study
the patients treated at Tampere University Hospital, where
patients treated with RAI have been systematically registered
since 1969. There were no register-based data available from
other hospitals in Finland. Tampere University Hospital has a
catchment population of 500,000 (10% of the Finnish pop-
ulation). The information on the etiology of hyperthyroidism,
previous surgical treatment, the dates and doses of RAI
treatments, and the follow-up data of thyroid function after
treatment have been collected in the register since 1969.
Following RAI treatment, the thyroid status of the patients
has been monitored by blood samples every one to three
months during the ﬁrst year and subsequently every one to
three years.
A control population was formed by randomly choosing
three age- (–6 months) and sex-matched control subjects for
each patient (treated with either RAI or thyroidectomy)
from the comprehensive national Population Register
Centre. The control subject had to reside in the same county
as the patient and to be alive at the time the patient was
treated. The total number of controls chosen was 18,432,
with 12,991 controls for the patients treated with thyroidectomy
and 5441 controls for the patients treated with RAI (Fig. 1).
The discharge diagnoses, as well as the dates of hospital
admissions before and after the treatment, were obtained
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from the nationwide HILMO database, with deterministic
record linkage based on the unique personal identiﬁcation
number assigned to all the residents of Finland. The HILMO
database includes hospitalizations (hospital admission re-
quiring an overnight stay) and causes of hospitalization of
the Finnish residents since January 1969 and the procedure
codes since 1986. Recording diagnoses to the HILMO da-
tabase is compulsory in Finland, and its completeness and
accuracy has been found to vary from satisfactory to very
good (11).
Both the primary and secondary diagnoses recorded at
discharge from the hospital were used in the analysis. The
diagnoses have been coded according to the Finnish version
of the eighth revision of the ICD (ICD-8) in 1986, the ninth
revision (ICD-9) up to 1995, and the 10th revision (ICD-10)
thereafter. A conversion between the different versions was
made, and the cardiovascular diagnostic codes were classi-
ﬁed into 10 major subgroups, which were analyzed sepa-
rately: any CVD, hypertension, coronary artery disease,
diseases of the pulmonary circulation, arrhythmias, heart
failure, cerebrovascular diseases, diseases of other arteries
and veins (including, for example, arteriosclerosis obliterans,
aortic aneurysms and dissections, and thrombosis of both
arteries and veins), and valvular diseases and cardiomyopa-
thies. Of the arrhythmias, atrial ﬁbrillation (AF) was also
studied separately. The follow-up ended on the date of the
ﬁrst hospitalization due to each CVD, the date of death,
emigration, or the common closing date (May 31, 2009),
whichever occurred ﬁrst.
The dates of death and emigration of the study subjects
were obtained from the Population Registration Centre using
computerized record linkage. The causes of death of the
patients and the controls were obtained from Statistics Fin-
land through record linkage. The dates and causes of death of
all deceased citizens certiﬁed by a physician have been in-
cluded in this register since 1971. The causes of death have
been coded according to the ICD. For the mortality analysis,
the underlying cause of death was used.
The study was undertaken in accordance with the De-
claration of Helsinki. No informed consent could be obtained
from the study subjects because of the large number of par-
ticipants and because many of them died before data col-
lection for the study. The ethics committee of the Pirkanmaa
Hospital District reviewed the study protocol. The National
Institute of Health and Welfare (THL) gave a permission to
use the data from the Hospital Discharge Registry.
Statistical analysis
Stata for Windows v13 (StataCorp, College Station, TX)
was used to calculate the hospitalization and mortality rates
for various CVDs. Cox regression analyses were performed
using IBM SPSS Statistics for Windows v23.0 (IBM Corp.,
Armonk, NY). A two-sided p-value of <0.05 was considered
statistically signiﬁcant. The differences in clinical charac-
teristics between the patients treated with RAI and the
thyroidectomized ones were estimated with a Mann–Whitney
U-test or chi-square test, as appropriate. Kaplan–Meier curves
were plotted to illustrate the hospitalization rates before and
after the treatment of hyperthyroidism, and mortality after the
treatment. Conditional logistic regressionmodelswere ﬁtted to
estimate the odds ratios (OR) of pretreatment hospitalization
due to different CVDs (i.e., prevalent CVDs at the time of
treatment). Cox regression analysis was used to estimate the
hazard ratios (HR) and conﬁdence intervals (CI) for CVD
hospitalizations, and mortality after the treatment for hyper-
thyroidism, adjusted for prevalent CVDs.
Results
A total of 6148 patients treated for hyperthyroidism be-
tween January 1986 and December 2007 were included in the
study. Of these, 4334 patients (5204 [85%] female) were
treated surgically in the whole of Finland, and 1814 patients
were treated with RAI at Tampere University Hospital. The
median age of the patients at the time of treatment and of the
corresponding controls was 49 years (interquartile range
[IQR] 35–63 years). The median age was 50 years (IQR
35–64 years) in men and 49 years (IQR 35–64 years) in
women. Sixteen percent (n = 988) of the patients and 15%
(n= 2675) of the controls died during the follow-up, and a total
of 177 subjects emigrated from Finland (Fig. 1). The median
follow-up time after the treatment for hyperthyroidism was
10.6 years for the patients and 10.4 years for the controls.
The clinical characteristics of the RAI-treated and thy-
roidectomized patient groups are described in Table 1. The
patients treated surgically were younger than the RAI-treated
ones (median age at the time of the treatment 46 vs. 59 years).
The sex distribution was quite similar, but the proportion of
nodular disease was higher in the surgically treated patients
(Table 1).
In Tampere University Hospital, 38 patients were treated
ﬁrst with RAI and then underwent surgery (2% of the RAI-
treated patients), and 145 patients were treated surgically
prior to RAI treatment (8% of the RAI-treated patients). No
information on RAI treatment among the surgically treated
patients was available from other Finnish hospitals. The pa-
tients treated ﬁrst with RAI and then surgically were analyzed
in the thyroidectomy group, and the patients treated ﬁrst with
thyroidectomy and then with RAI were analyzed in the RAI
group.
CVD hospitalizations before the treatment
of hyperthyroidism
The difference in hospitalization rates between the pa-
tients (treated with either thyroidectomy or RAI) and the
controls due to any CVD started to increase several years
before the treatment of hyperthyroidism (Fig. 2). The risk of
CVD hospitalization was increased by the time of the
treatment in most of the subgroups of CVDs in the hyper-
thyroid patients compared to the controls (Table 2). The
subgroup of CVDs most frequently associated with hospi-
talization before the treatment was hypertension. The
hypertension-associated hospitalizations were 75% higher
in the hyperthyroid patients compared to the controls at the
time of the treatment. The second most frequent subgroup of
CVDs consisted of arrhythmias, of which AF was the most
common one. By the time of the treatment of hyperthy-
roidism, the OR for hospitalization due to AF was ﬁvefold
(OR = 5.13 [CI 4.39–6.00]) in the patients compared to the
controls (Table 2). When the treatment groups (RAI or
thyroidectomy) were separately compared to their own age-
and sex -matched controls, a similar increase was seen in
both treatment groups in hospitalizations due to any CVD,
HYPERTHYROIDISM AND CARDIOVASCULAR MORBIDITY AND MORTALITY 1113
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A B
C
FIG. 2. (A–C) Cumulative
hospitalization rate due to
different cardiovascular dis-
eases 10 years before and
>20 years after the treatment
of hyperthyroidism com-
pared to the age- and sex-
matched control group
(log-rank test).
Table 1. Clinical Characteristics of the Hyperthyroid Patients Treated with Thyroidectomy or RAI
Thyroidectomy, n = 4334 RAI, n= 1814
n % n % p-Value
Median age, years (Q1–Q3) 46 (33–59) 59 (44–71) <0.001*
Sex <0.001**
Male 615 14 329 18
Female 3719 86 1485 82
Etiology of hyperthyroidism <0.001**
Graves’ disease 2070 48 1022 56
Nodular disease 1697 39 319 18
Unspeciﬁed 567 13 473 26
Type of surgery
Near-total 1347 31
Total 2943 68
Both 44 1
*Mann–Whitney U-test.
**Chi-square test.
RAI, radioactive iodine.
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hypertension, or arrhythmias before the treatment of hy-
perthyroidism. The risk of hospitalization due to most other
CVDs was also increased in the RAI-treated patients, but
not in the thyroidectomized patients, compared to the re-
spective control group (Table 2).
CVD hospitalizations after the treatment
of hyperthyroidism
There were a total of 1719 hospitalizations due to any
new CVD among the patients after the treatment of hyper-
thyroidism and 4408 hospitalizations among the controls.
The risk of hospitalization due to any CVD was slightly but
signiﬁcantly higher among the patients compared to the
controls during the follow-up when adjusted for prevalent
CVDs at the time of treatment (HR = 1.15 [CI 1.09–1.21]).
However, the risk clearly decreased when compared to the
pretreatment risk of hospitalization due to CVDs (HR = 1.61
[CI 1.49–1.79]).
The most common subgroup of CVDs leading to hospi-
talization after treated hyperthyroidism among all the pa-
tients was arrhythmias (680 hospitalizations in the patients
and 1275 in the controls), and the next most common was
hypertension (668 hospitalizations in the patients and 1590 in
the controls). The risk of hospitalization due to hypertension,
arrhythmias, heart failure, cerebrovascular diseases, diseases
of other arteries and veins, and valvular diseases and car-
diomyopathies was slightly higher in the patients when ad-
justed for the prevalent hospitalizations due to the same
disease prior to the treatment of hyperthyroidism. However,
the risk of hospitalization for AF, coronary artery disease, or
the diseases of pulmonary circulation was no longer in-
creased after treated hyperthyroidism (Table 3).
In separate analyses of the two treatment groups, the pa-
tients treated with RAI remained at an increased risk of CVD
hospitalization due to any CVD, hypertension, arrhythmias,
heart failure, cerebrovascular diseases, diseases of other ar-
teries and veins, and valvular diseases and cardiomyopathies
Table 2. Odds Ratios for Cumulative Hospitalization Rates Prior to Treatment due to
Different CVDs in Patients Treated for Hyperthyroidism Compared to
Age- and Sex-Matched Controls
RAI-treated patients
(n = 1814) vs.
controls (n = 5441)
Thyroidectomy-treated
patients (n= 4334) vs.
controls (n = 12,991)
All patients (n = 6148)
vs. all controls (n = 18,432)
CVD OR [CI] p-Value OR [CI] p-Value OR [CI] p-Value
Any CVD 1.81 [1.61–2.01] <0.001 1.50 [1.37–1.64] <0.001 1.61 [1.49–1.73] <0.001
Hypertension 1.50 [1.23–1.84] <0.001 2.05 [1.67–2.51] <0.001 1.75 [1.52–2.02] <0.001
All arrhythmias 4.31 [3.52–5.27] <0.001 3.93 [3.20–4.81] <0.001 4.12 [3.57–4.75] <0.001
Atrial ﬁbrillation 5.86 [4.64–7.40] <0.001 4.60 [3.72–5.67] <0.001 5.13 [4.39–6.00] <0.001
Diseases of arteries and veins 1.15 [0.99–1.33] 0.068 1.10 [0.95–1.28] 0.212 1.13 [1.01–1.25] 0.026
Coronary artery disease 1.67 [1.36–2.05] <0.001 0.80 [0.56–1.15] 0.412 1.37 [1.18–1.60] <0.001
Cerebrovascular diseases 1.60 [1.23–2.07] <0.001 1.12 [0.95–1.32] 0.231 1.23 [1.00–1.52] 0.045
Heart failure 2.86 [2.19–3.72] <0.001 1.92 [1.22–3.00] 0.050 2.59 [2.06–3.25] <0.001
Valvular diseases and cardiomyopathiesa 3.52 [2.14–5.77] <0.001 1.57 [0.98–2.51] 0.056 2.28 [1.63–3.19] <0.001
Diseases of pulmonary arteries 1.63 [0.85–3.14] 0.145 1.56 [0.80–3.04] 0.213 1.60 [1.00–2.55] 0.051
aNonbacterial endo-, peri and myocardial diseases, including valvular diseases and cardiomyopathy.
CVD, cardiovascular disease; OR, odds ratio; CI, conﬁdence interval.
Table 3. Hazard Ratios and p-Values for Hospitalization Rates due to Different CVDs
After Treatment of Hyperthyroidism in Patients Compared to Age- and Sex-Matched
Controls and Adjusted for Prevalent CVDs
RAI-treated
patients (n= 1814) vs.
controls (n= 5441)
Thyroidectomy-treated
patients (n = 4334) vs.
controls (n = 12,991)
All patients (n = 6148)
vs. all controls
(n = 18,432)
CVD HR [CI] p-Value HR [CI] p-Value HR [CI] p-Value
Any CVD 1.23 [1.13–1.34] <0.001 1.11 [1.03–1.19)] 0.006 1.15 [1.09–1.21] <0.001
Hypertension 1.26 [1.09–1.44] <0.001 1.18 [1.05–1.33] 0.005 1.21 [1.10–1.32] <0.001
All arrhythmias 1.19 [1.03–1.37] 0.019 1.14 [0.99–1.30] 0.064 1.14 [1.04–1.26] 0.007
Atrial ﬁbrillation 1.08 [0.92–1.28] 0.350 0.98 [0.84–1.15] 0.820 1.02 [0.91–1.15] 0.700
Diseases of arteries and veins 1.22 [1.02–1.45] 0.027 1.11 [0.98–1.26] 0.100 1.15 [1.04–1.27] 0.009
Coronary artery disease 1.11 [0.97–1.28] 0.135 1.03 [0.91–1.18] 0.610 1.07 [0.97–1.17] 0.193
Cerebrovascular diseases 1.35 [1.12–1.62] 0.002 1.19 [0.99–1.41] 0.064 1.22 [1.08–1.38] 0.001
Heart failure 1.25 [1.05–1.48] 0.012 1.14 [0.97–1.34] 0.121 1.16 [1.03–1.32] 0.019
Valvular diseases and cardiomyopathiesa 1.69 [1.23–2.32] 0.001 1.51 [1.16–1.95] 0.002 1.57 [1.29–1.92] <0.001
Diseases of pulmonary arteries 0.96 [0.64–1.45] 0.857 0.77 [0.52–1.13] 0.176 0.85 [0.64–1.12] 0.242
Statistically signiﬁcant values are shown in bold.
aNonbacterial endo-, peri and myocardial diseases, including valvular diseases and cardiomyopathy.
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compared to their age- and sex-matched controls. The thy-
roidectomized patients had an increased risk of CVD hospi-
talization due to any CVD, hypertension, and valvular
diseases and cardiomyopathies, but not due to any other
subgroup of CVDs (Table 3).
Comparison of CVD hospitalizations between
the RAI-treated and the thyroidectomized group
The risk of hospital admission due to CVDs after the
treatment of hyperthyroidism was somewhat higher among
the RAI-treated patients compared to the patients treated with
thyroidectomy when adjusted for age, sex, and prevalent
CVDs (HR = 1.14 [CI 1.03–1.26]; Table 4). Additional ad-
justment for the etiology of hyperthyroidism did not change
the result (HR = 1.17 [CI 1.05–1.30]; Table 4). The risk of
hospitalization due to arrhythmias (HR = 1.21 [CI 1.03–
1.42]) and new-onset AF (HR = 1.29 [CI 1.08–1.54]) was also
increased in the RAI-treated patients compared to the surgi-
cally treated ones, but there were no signiﬁcant differences in
the other CVD subgroups (Table 4).
To test whether the differences in CVD hospitalizations
could be due to the geographical differences between the
RAI-treated and the thyroidectomized group, the same ana-
lyses were performed in the control groups. There was no
difference in the risk of hospital admission due to CVDs
when the controls of the RAI-treated patients were compared
to the controls of the thyroidectomized patients when ad-
justed for age, sex, and prevalent CVDs (HR = 0.97 [CI 0.91–
1.03]), excluding any signiﬁcant effect of the geographical
difference on the results.
Forty-seven percent (n= 855) of the RAI-treated patients
started levothyroxine replacement therapy during the follow-
up, indicating that RAI treatment had resulted in hypothy-
roidism. The rest of the patients (n = 959) either had a relapse
of hyperthyroidism or became euthyroid without thyroid
hormone replacement therapy. In a subgroup analysis in-
cluding only the patients with RAI-induced hypothyroidism
and all the surgically treated patients, there was no difference
in the risk of CVD hospitalizations between the treatment
groups (relative risk [RR] = 0.95 [CI 0.82–1.09]; Table 4).
The result did not change in an analysis including only the
patients treated with total (RR = 0.98 [CI 0.79–1.21]) or near-
total (HR = 0.96 [CI 0.81–1.13]) thyroidectomy. The patients
treated ﬁrst with near-total and then with total thyroidectomy
(n = 44 patients; 1% of all thyroidectomized patients) were
not included in these analyses.
CVD mortality
Despite the increased CVD morbidity, there was no dif-
ference in the overall CVD mortality between all the hyper-
thyroid patients and the age- and sex-matched controls
(HR = 1.06 [CI 0.96–1.18]; Fig. 3A; p= 0.284). The result
remained similar when adjusted for the prevalent CVDs
(HR = 0.93 [CI 0.84–1.03]) at the time of treatment, and in
subgroup analyses by age and etiology (data not shown). In
the analyses of different treatment groups compared to their
controls, the patients treated with RAI had a higher CVD
mortality rate compared to their respective controls (Fig. 3B;
p = 0.004). However, CVD mortality among the patients
treated with thyroidectomy (Fig. 3C; p = 0.228) and the
patients treated with RAI to hypothyroidism (Fig. 3D;
p = 0.053) was comparable to their control groups.
In a Cox regression analysis, cardiovascular mortality
was signiﬁcantly higher in the patients treated with RAI
compared to the patients treated with thyroidectomy when
adjusted for age, sex, and prevalent CVD (HR = 2.05 [CI
1.69–2.48]). The result was unaffected by adjustment for the
etiology of hyperthyroidism (HR = 2.56 [CI 2.08–3.15]) or
by including only the patients treated with near-total
(HR= 2.05 [CI 1.67–2.52]) or total thyroidectomy (HR= 3.17
[CI 2.16–4.65]).
There was no difference, however, in the mortality rate
between the patients treated effectively with RAI (resulting
in levothyroxine-treated hypothyroidism) and those treated
with total thyroidectomy (HR = 0.58 [CI 0.34–1.00]). In this
analysis, there was no statistically signiﬁcant difference in
Table 4. Hazard Ratios for Hospitalizations due to Different CVDs After Treatment
of Hyperthyroidism with RAI Compared to Patients Treated with Thyroidectomy
and Adjusted for the Age at Time of Treatment, Sex, Prevalent CVDs,
and Etiology of Hyperthyroidism
RAI (n= 1814) vs.
thyroidectomy (n = 4334)
RAI resulting in
hypothyroidism (n= 855) vs.
thyroidectomy (n = 4334)
RAI not resulting in
hypothyroidism (n = 959) vs.
thyroidectomy (n= 4334)
CVD HR p-Value HR p-Value HR p-Value
All CVDs 1.17 [1.05–1.30] 0.005 0.95 [0.81–1.11] 0.534 1.28 [1.13–1.43] <0.001
Hypertension 1.02 [0.86–1.21] 0.802 1.00 [0.78–1.27] 0.968 1.08 [0.89–1.30] 0.436
All arrhythmias 1.32 [1.12–1.57] 0.001 1.12 [0.86–1.46] 0.389 1.35 [1.13–1.62] <0.001
Atrial ﬁbrillation 1.40 [1.16–1.68] <0.001 1.23 [0.90–1.66] 0.191 1.44 [1.18–1.75] <0.001
Diseases of arteries and veins 0.94 [0.76–1.16] 0.561 1.02 [0.78–1.33] 0.882 0.84 [0.65–1.08] 0.178
Coronary artery disease 0.99 [0.83–1.19] 0.935 0.70 [0.52–0.94] 0.019 1.13 [0.93–1.37] 0.227
Cerebrovascular diseases 1.05 [0.83–1.32] 0.718 0.74 [0.51–1.07] 0.112 1.20 [0.93–1.54] 0.161
Heart failure 1.14 [0.89–1.44] 0.299 0.78 [0.53–1.15] 0.201 1.30 [1.01–1.68] 0.039
Valvular diseases and
cardiomyopathies
1.15 [0.79–1.67] 0.466 0.80 [0.45–1.45] 0.467 1.25 [0.84–1.85] 0.272
Diseases of pulmonary arteries 1.67 [0.95–2.94] 0.074 2.34 [1.16–4.71] 0.017 1.03 [0.53–1.99] 0.941
Statistically signiﬁcant values are shown in bold.
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A B
C
E
D
FIG. 3. (A–E) Cumulative cardiovascular mortality rate by time since the treatment of hyperthyroidism in the different
groups of patients compared to the age and sex-matched control group (log-rank test).
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the subgroup of patients with nodular disease compared to the
patients with Graves’ disease (HR = 1.48 [CI 0.75–2.92]).
In an additional analysis including only the patients with
Graves’ disease treated effectively with RAI (resulting in
levothyroxine-treated hypothyroidism) and the Graves’ dis-
ease patients treated surgically, the risk of death due to any
CVD was signiﬁcantly lower in the RAI-treated patients
when adjusted for age, sex, and prevalent CVDs (RR = 0.43
[CI 0.23–0.78]). However, by including only the Graves’
disease patients treated with total thyroidectomy (resulting in
levothyroxine-treated hypothyroidism), there was no differ-
ence in mortality rate compared to the Graves’ disease pa-
tients treated with RAI (HR = 1.37 [CI 0.51–3.70]).
To test for the geographical differences between the two
groups of patients, the risk of CVD mortality of the controls
of the RAI-treated patients was compared to the CVD mor-
tality of the controls of the thyroidectomized patients and
adjusted for age, sex, and prevalent CVDs. There was no
signiﬁcant difference in this analysis (HR = 0.98 [CI 0.89–
1.12]), excluding any signiﬁcant effect of the geographical
difference on the results.
Discussion
There are a few previous studies on long-term CVD
morbidity and mortality in hyperthyroid patients treated with
RAI, but only two of them included patients treated with
thyroidectomy for hyperthyroidism (12,13). In the present
study study, cardiovascular morbidity already increased
several years before the treatment of hyperthyroidism in both
groups of patients. The risk was attenuated by both treatment
modalities, but the increased CVD morbidity still lasted for
two decades after the treatment of hyperthyroidism. Themain
ﬁnding in this study is that of increased CVD morbidity and
mortality in the RAI-treated patients compared to those
treated with thyroidectomy. Cardiovascular morbidity or
mortality did not differ between the treatment modalities if
the treatment with RAI resulted in (levothyroxine-treated)
hypothyroidism.
After the treatment of hyperthyroidism, the RAI-treated
patients had a signiﬁcantly higher risk of CVD hospitaliza-
tion and mortality compared to the surgically treated patients.
The patients treated with thyroidectomy were younger than
those receiving RAI, but the results were adjusted for age and
other clinical differences between the groups. Thyroid sur-
gery is an effective treatment modality for hyperthyroidism,
offering a predictable, high cure rate (13,14). The onset of
euthyroidism is immediate after surgery, and levothyroxine
therapy is started without delay if needed. After RAI treat-
ment, thyroid function usually returns to normal within two
to six months, and hypothyroidism develops within 4–12
months or even later (15). Thus, the RAI-treated patients may
be either hypo- or hyperthyroid for longer time periods, al-
lowing the stress in the cardiovascular system to last longer,
compared to the thyroidectomized patients. This might ex-
plain the better prognosis of the patients treated surgically for
hyperthyroidism. This explanation is supported by the better
prognosis of the patients treated effectively with RAI (re-
sulting in levothyroxine-treated hypothyroidism) compared
to the patients treated surgically in this study.
Both treatment modalities are widely used, but the patients
treated surgically for hyperthyroidism differ from the patients
treated with RAI in several aspects. The underlying thyroid
disease, patient preferences, as well as the age and the op-
erative risks of the patient are taken into account when
choosing the treatment modality. In Finland, most hyper-
thyroid patients have been treated with RAI over the past few
decades. Thyroidectomy may have been chosen if the patient
had a large goiter with compressive symptoms, a suspicion of
malignancy, severe eye symptoms of Graves’ disease, or
hyperthyroidism resistant to antithyroid medication during
pregnancy. Due to different patient selection for the different
treatment modalities, the treatment groups are not totally
comparable in a nonrandomized, register-based study, and
there is a possibility for confounding by indication. In this
study, however, the results were adjusted for the main clinical
variables, including age, sex, prior CVDs, and the etiology of
hyperthyroidism.
In hyperthyroidism, cardiac output increases substantially
as a result of increased heart rate and contractility, together
with decreased peripheral resistance and increased venous
return and preload (16). Most changes in the cardiovascular
system during hyperthyroidism are adaptive responses to
increased energy metabolism and heat production in the
body. Nevertheless, as a result of this adaptation, the car-
diovascular system is strained already in resting conditions,
leading to exercise intolerance, even in otherwise healthy
persons (17). AF, tachycardia, elevated blood pressure, in-
creased blood volume, and increased oxygen demands of the
heart predispose to heart failure and to worsening of the
symptoms of a coexisting heart disease (16,18,19). Based on
this and previous studies on hyperthyroid patients (1,2,4,7,8),
changes in the cardiovascular system during the hyperthyroid
phase result in increased CVD morbidity and also mortality,
even after restoring euthyroidism, although the mechanisms
of the persistent risk remain unclear. In the present study,
CVD morbidity was already increased years before the
treatment. Similar results have been reported in a Danish
study on hyperthyroid patients (20), which emphasizes the
importance of a timely diagnosis of hyperthyroidism, espe-
cially among patients with cardiovascular symptoms, to
prevent permanent impairment. Likewise, these patients
should be considered at high risk for future CVDs, despite the
treatment of hyperthyroidism. An active follow-up for other
risk factors and for new cardiovascular symptoms of previ-
ously hyperthyroid patients are warranted.
The risk of new-onset AF remained higher in patients
treated with RAI compared to patients treated with thyroid-
ectomy. There was, however, no difference in the risk of new-
onset AF between the patients treated with RAI to permanent
hypothyroidism and those who underwent thyroidectomy.
The risk of AF is increased in hyperthyroidism, and the
prevalence also increases with age (21). After thyroidectomy,
eu- or hypothyroidism is achieved faster than after RAI
treatment, leading to a shorter exposure to the pro-arrhythmic
effects of hyperthyroidism. A Danish study showed that
the risk of AF is associated with thyroid function across
the spectrum of subclinical and clinical thyroid diseases,
the incidence of AF increasing with a decreasing thyro-
tropin (TSH) level (22). The risk of recurrent clinical or
subclinical hyperthyroidism is lower after thyroidec-
tomy than after RAI treatment, probably explaining the
lower risk of new-onset AF among patients treated with
thyroidectomy.
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CVD mortality was similar between the hyperthyroid pa-
tients and their age- and sex-matched controls. This contra-
dicts previous studies reporting increased CVD mortality in
hyperthyroid patients (3–5,8). The previous studies, how-
ever, were conducted mainly on patients treated with RAI.
The majority of the patients in this study were treated with
thyroidectomy, which may have affected the result. In a
previous study on patients treated with thyroidectomy, there
was no signiﬁcant difference in CVD mortality between the
patients and their age- and sex-matched controls (1). In the
present study, CVD mortality was twice as high in RAI-
treated patients compared to the patients treated with thy-
roidectomy, adjusted for the clinical features (age, sex, the
etiology of hyperthyroidism, and prevalent CVDs prior to
treatment). The excess risk was eliminated by effective
treatment with RAI, resulting in hypothyroidism. The in-
creased CVD mortality among the RAI-treated patients may
thus reﬂect an ineffective or too slow restoration of the nor-
mal cardiovascular function after treatment with RAI in
many hyperthyroid patients. Nevertheless, levothyroxine-
treated hypothyroidism after treatment with RAI seemed to
protect against the risk of CVD death. Similarly, decreased
cardiovascular morbidity associated with the development of
hypothyroidism in RAI-treated patients has been reported
previously (5,7,9). This indicates that effective treatment of
hyperthyroidism has a major impact on the cardiovascular
prognosis of patients. In a large Danish register-based study
of TSH measurements in 239,678 individuals, a 9% excess
overall mortality was detected for each six-month period with
low TSH levels. An excess mortality was also associated with
elevated TSH measurements, highlighting the importance of
euthyroidism for prognosis (23). Likewise, a recent study
based on the same Danish register data reported an increased
risk of mortality in both treated and untreated hyperthyroid-
ism. There was an association between cumulative periods of
low TSH and mortality. As the authors state, the excess
mortality associated with hyperthyroidism may not be due to
a lack of therapy, but rather to an inability to keep the patients
euthyroid (24). Giesecke et al. (12) presented a similar in-
terpretation of the effect of hyperthyroidism per se and not
the treatment modality on CVD morbidity and mortality in a
recently published study of 12,239 hyperthyroid patients.
They found a 12% increase in CVDmorbidity, but also a 27%
increase in CVD mortality in hyperthyroid patients treated
with either RAI or thyroidectomy compared to patients
treated with thyroidectomy for nontoxic goiter.
The strengths of this study are the complete and relatively
long follow-up and a large patient cohort. There are, how-
ever, some limitations to this study. The results are based on
register data. Because of the nature of the study, it was not
possible to adjust the results for the common risk factors of
CVDs, including smoking, family history, diabetes, or med-
ication. Smoking is a common confounding factor, and it is
also a shared risk factor for CVD and hyperthyroidism,
mainly Graves’ disease (25,26). This may have resulted in
overestimation of the risk of CVDs in the patients with hy-
perthyroidism compared to the age- and sex-matched con-
trols, but is unlikely to have confounded the comparisons
between the two treatment modalities because the results
were adjusted for the etiology of hyperthyroidism. Informa-
tion on the results of any laboratory tests after thyroidectomy
or RAI was not available. Therefore, it was not possible to
identify relapses of hyperthyroidism after thyroid surgery.
Information on the treatment response of the levothyroxine
treatment after thyroid surgery was also lacking. Both under-
and overtreatment of hypothyroidism could increase the risk
of CVDs. Finally, the thyroidectomy group consisted of pa-
tients treated in the whole of Finland, but the RAI group
included only patients treated at Tampere University Hos-
pital. The geographical difference is, however, unlikely to
have affected the results due to broad adherence to the na-
tional guidelines on the treatment of hyperthyroidism and
CVDs in Finland. In line with this view, there was no dif-
ference in the risk of CVD hospitalization or CVD mortality
between the controls from the Tampere University Hospital
catchment area and those from the whole of Finland. Fur-
thermore, virtually all the patients are treated with antithyroid
medication before the deﬁnitive treatment for hyperthyroid-
ism, regardless of the treatment modality chosen.
In conclusion, hyperthyroidism increases cardiovascular
morbidity compared to age- and sex-matched controls. The
risk can be decreased by effective treatment of hyperthy-
roidism. The results underline the importance of an imme-
diate and efﬁcient management of hyperthyroidism and an
active follow-up for cardiovascular risks after the treatment
for hyperthyroidism.
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